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Abstract 
Work in our lab has resulted in the development of a novel approach to creating a more 
developmentally plastic human dermal fibroblast (hDF) phenotype that allows for the 
study of molecular mechanisms involved in cell-fate conversion. Culturing hDF under 
defined culture conditions (5% O2 and supplementation with fibroblast growth factor 
FGF2) induces induced the regeneration competent (iRC) phenotype that is 
characterized by stem cell gene expression, and increased life-span in vitro. The work 
presented in this thesis further characterizes the system, and describes an overall shift 
in extracellular matrix and adhesion molecules in human dermal fibroblasts (hDF) 
undergoing the transition to a more developmentally plastic phenotype (iRC). This work 
suggests that we create the initiation phase of Mesenchymal-to-Epithelial Transition 
(MET) during conversion to the iRC phenotype. This transition is marked by loss of 
integrin alpha-11 (α11) and its binding partner Collagen-I (COL-I). Moreover, we 
describe the mechanism for the down-regulation of α11 that is mediated by FGF2 
activation of ERK1/2 through systematic investigation of several potential molecular 
mechanisms. The body of work presented here shows that the ERK 1/2 mediated down-
regulation of α11 is independent of activation of TGF-β1-mediated regulation of α11. In 
addition to down-regulation of α11, an overall shift in the transcript levels of other 
adhesion molecules is observed, which demonstrates that iRC are most likely 
transitioning their attachment to a laminin and fibronectin-based matrix. These results 
suggest that iRC may be producing a more “pro-regenerative matrix”. We hypothesize 
that the changes in integrin expression profile and interaction with ECM serve as a 
feedback loop during the iRC phenotype shift. Our findings suggest that this “pro-
regenerative” shift in attachment of iRC as well as the ERK 1/2 mediated down-
regulation of α11 could be exploited in wound healing biology and fibrosis research. 
Manipulation of the dynamic relationship between TGF-β1 and FGF2 has the potential to 
reduce scar deposition. Further identification of molecular mechanisms controlling this 
phenotype conversion will allow development of strategies for in situ manipulation of 
wound healing outcomes. 
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Chapter 1 
Background and Literature Review 
2 
1.0 Introduction 
Discoveries that have enabled the conversion of mammalian somatic cells towards a 
less specialized cell type with higher developmental potential hold great therapeutic potential 
encompassing a broad range of applications. Induced acquisition of multipotency or 
pluripotency not only allows for generation of an autologous cell source and patient-specific 
disease modeling, it also creates the opportunity to address a diverse range of developmental 
biological questions that could not be studies previously due to unavailability of suitable models.  
We have developed a novel approach to creating a more developmentally plastic human 
dermal fibroblasts (hDF) phenotype that allows us to study the molecular mechanisms involved 
in cell-fate conversion. Culturing hDF under defined culture conditions (5% O2 and 
supplementation with fibroblast growth factor FGF2) induces stem cell gene expression, and 
increases their life-span in vitro. The iRC cells maintain a normal karyotype and do not form 
tumors when injected into severe combined immunodeficiency – SCID - animals.  The 
developmental plasticity of cells cultured under these conditions has led us to call them induced 
regeneration competent cells (iRC). This plasticity has been demonstrated by transplantation 
into a murine volumetric skeletal muscle wound where they engraft, acquire expression of a 
muscle satellite stem cell marker PAX7, and instead of significant collagen deposition and scar 
formation contribute to wound healing by functional regeneration of skeletal muscle [1]. 
The ability of the iRC’s to profoundly alter the outcome of a wound healing process from 
scar formation to regeneration prompted the work presented in this thesis, namely to investigate 
the role of low oxygen and FGF2 culture system in regulation of extracellular matrix (ECM) and 
adhesion molecules (AM) that may be involved in the fibroblast phenotype conversion. 
3 
1.1 Regenerative Medicine—Eliciting functional regeneration as a response tissue 
damage  
Regenerative medicine dates back to early 3rd century writings. For as long as we have 
written records, it is clear that doctors and scientists alike have been aware of the need for 
regenerative medicine as a means to replace damaged or diseased parts of the body. 
Regenerative medicine has developed in parallel with modern medicine, with the most critical 
landmark being in the field of tissue engineering, when Johann Friedrich Dieffenbach in 1882 
performed the first skin transplantation in animal models [2]. 
A major development that significantly affected the field of regenerative medicine was 
the ability to grow human embryonic stem cells in vitro [3]. This discovery marked an important 
milestone not only in the stem cell biology field, but in clinical research and personalized 
medicine as well [3]. Groundbreaking work in the field of reproductive biology leading to the 
development of somatic cell nuclear transfer technology [4] changed the way clinicians and 
scientists viewed the potential for regenerative medicine.  
1.1.1 Degenerative diseases 
Human diseases that can be treated by the stem cell-based therapies are a diverse, 
broad range of diseases. Stem-cell based therapy have potential applications in treating 
hematopoietic disorders, ranging from cancers such as leukemia and myeloma, to various forms 
of anemia related disorders [5]. Stem-cell based therapies offer hope for neurological 
degenerative disorders such as Parkinson’s and Alzheimer’s, as well as spinal cord injury and 
multiple sclerosis [6]. They have also been implicated to as potential therapies for diabetes 
mellitus as well as a broad range of other degenerative disorders of the eyes, liver, lungs, and 
skin.  
Animal studies using embryonic stem cells differentiated into photoreceptors in vitro and 
transplanted into blind animals showed good integration [7], and currently similar technology is 
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being used in clinical trials where retinal pigmented epithelial (RPE) cells are currently being 
derived from human embryonic stem cells [8] and transplanted into damaged cornea of patients 
for treatment of dry age-related macular degeneration. This is the first therapy in humans to 
demonstrate efficacy using human embryonic stem cells. Early results from these clinical 
studies have shown that human embryonic-derived RPE cells can repair and restore vision in 
patients [9-11].   
Recent studies aiming at the use of stem cells for treating myocardial infarction have 
gained importance, and animal studies have demonstrated very positive outcomes for treatment 
of myocardial infarctions with stem cells or stem cell-derived cardiovascular cells. Several 
studies in patients suffering from acute myocardial infarction are exploring the use of autologous 
bone marrow stem cells or hematopoietic stem cells in combination with current 
pharmacological and surgical interventions. Early results from these studies are very 
encouraging and have demonstrated improvements over standard approaches [12, 13].  
1.1.2 Injury and Wound Healing 
Skeletal muscle has a large potential for regeneration following injury, however few 
effective therapeutic options exist for traumatic injury resulting in volumetric muscle loss. When 
more than 20% of the muscle tissue is lost, injury results in the natural repair process failing, 
and accumulation of scar tissue, and damage to the surrounding muscle tissue [14-18]. 
Autologous muscle grafts or muscle transposition represent two possibilities of salvaging 
procedures for the restoration of tissue function, but at best they have limited success [19].  
Most cell-based therapies are still in their infancy, and a large need exists for regenerative 
strategies based in cell therapy applications for regeneration of skeletal muscle after volumetric 
muscle loss. Most work that has been done in repairing muscle functionality using stem cell-
based therapies has been treating degenerative diseases such as muscular dystrophies [20-24]. 
There is still a need for a translational application for the isolation, expansion and maintenance 
5 
of myogenic cells from an autologous cell source for the treatment of volumetric muscle loss, as 
it requires a larger cell source than the treatment of degenerative diseases [25] . 
The ultimate goal of the treatment of cutaneous burns and wounds is to restore the 
damaged skin both structurally and functionally to its original state. Recent research advances 
have shown the great potential of stem cells in improving the rate and quality of wound healing 
and regenerating the skin and its appendages. Stem cell-based therapeutic strategies offer new 
prospects in the medical technology for burns and wounds care. With regard to its therapeutic 
implication in skin, an earlier preclinical study has demonstrated that human ESCs can be 
differentiated into fully functional keratinocytes and thus can be used to grow epidermis in 
vitro and provide temporary skin substitutes for patients awaiting autologous skin grafts [26]. In 
a recent study, it was validated that iPSC’s could be derived from fibroblasts of patients with an 
inherited genetic disease characterized by recurrent blistering skin wounds. Moreover they 
showed that these iPSCs were able to generate 3D skin equivalents in vitro suggesting 
functionality [27]. The validation of this iPSC therapy proves that iPSC can be a source for the 
generation of keratinocytes for stem cells for wound healing applications.  
Stem cells have been utilized in a few regenerative skin applications. Reports published 
in 2005 described healing of an extensive skin burn after transplantation of bone marrow 
derived mesenchymal stem cells [28]. There is a need for treatment methods for patients with 
extensive skin burns, which would be lifesaving, but engineered skin is not structurally and 
functionally equivalent to normal skin and so ongoing studies are exploring whether iPSC’s 
could be used to bridge this gap. iPSCs derived from different cell types of the skin could then 
be combined and differentiated into all the cell types of the skin allowing a more effective 
regeneration of damaged skin [29].  
6 
1.2 Regenerative Medicine—Search for a cell source 
1.2.1 Pluripotent Cell Sources 
Human embryonic stem cells (hESC) are derived from the inner cell mass of a blastocyst 
and in vitro can serve as a self-renewing source of pluripotent cells. Pluripotent cell sources 
offer the ability to differentiate into any of the three germ layers: endoderm, mesoderm and 
ectoderm [30]. The development and study of methods for culturing hESC created a path to 
advancements in regenerative medicine. In addition to their therapeutic potential, hESC offer 
the ability to study unique biological systems and disease models that were very difficult to 
reproduce prior to hESC culture development.  
Human embryonic stem cells in vitro grow in colonies that are composed of highly 
adherent pluripotent progenitors, where pluripotency is maintained through a defined culture 
system with a large component being the presence of a mouse embryonic feeder layer, or a 
combination of purified extracellular matrix substrates [31]. Dissociation of cell-cell attachments 
in hESC colonies leads to an increased rate of differentiation, and cell death. This need for 
attachment both by extracellular contact and cell-cell contact suggest that both substrate and 
cell-cell adhesion are seminally involved in the assembly and maintenance of pluripotent human 
embryonic stem cell colonies [32].  
The large number of benefits and the future potential that hESCs provide for the 
regenerative biology community and the field of drug discovery research are met with a list of 
ethical problems and limitations. As a result of these limitations, large research efforts were 
focused in developing pluripotent stem cells from other sources. These research efforts resulted 
in the discovery of induced pluripotent stem cells (iPSC).  
iPSCs were originally generated by use of viral vectors, which introduced four key 
reprogramming factors (OCT3/4 and SOX2, with either a combination of KLF4 and C-MYC or 
NANOG and LIN28) into skin fibroblasts [33, 34]. Addition of these reprogramming factors 
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induces an embryonic-like state where cells can be passaged in culture indefinitely while 
retaining their pluripotency, or be differentiated into one of the three germ layers through varying 
media compositions, presence of cytokines, and extracellular matrix substrate [33, 34]. 
Regenerative medicine has given increased attention to the potential of iPSC in recent years.  
Potential therapies and technologies using cells that have been reprogrammed to an alternate 
fate could provide immune-matched cells for transplantation therapy, advancements in drug 
development, generation of a multitude of cell types for drug compound screening, and the 
Figure 1.1 Schematic of iPSC induction 
Adult somatic cells are reprogrammed through various methods to give rise to induced 
pluripotent stem cells which can be further differentiated into various cell types for therapeutic 
application and drug screening. 
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ability to study disease pathology through cell lines which are reproducible, and definable 
(Figure 1.1).  However the successful implementation of personalized therapies employing iPSC 
technology depends on the generation of cells that are free of all safety and ethical concerns. 
As a method of direct reprogramming by defined-factors, iPSCs hold the potential for forward 
progress in regenerative medicine. However, to date, major roadblocks exist which limit the use 
of iPSC from derivation sources that are available [35, 36].  
Much work is needed before cell lines derived from iPSC can their reach full therapeutic 
potential in personalized cellular therapy. Some progress has been made at varying success 
rates in the derivation of cell lines from iPSC through cell type specific differentiation protocols. 
Most differentiation protocols involve successful differentiation of hESCs and iPSC into 
functional hepatocytes both in vitro and in vivo [37-39], lung epithelium [40, 41] insulin secreting 
cells [42, 43], functional neurons [44, 45] as a treatment for many neurodegenerative diseases, 
and potentially restore injury from damage to the spinal cord (Figure 1.2).  
To this end, progress towards defining novel methods for generation of a clinically 
complaint, autologous cell source is necessary. Moreover, understanding the molecular 
mechanisms underlying cell-fate and cell-fate reversal is critically important to the field of 
regenerative medicine for therapeutic advancement utilizing pluripotent cell lines as therapies. 
In addition to attachment for maintaining pluripotency, human embryonic stem cells are 
dependent on the addition of basic fibroblast growth factor 2 (FGF2) from either exogenous 
supplementation, mouse embryonic fibroblast conditioned culture medium, or a combination of 
the two [46, 47]. Recently, the methods for derivation and maintenance of stem cells have 
shifted focus to the importance of the environmental cues, with emphasis on the role of 
extracellular matrix (ECM) and adhesion molecules (AM) [48]. 
9 
1.2.2 Multipotent cell sources- 
Adult stem cells have become an attractive source for cell therapy as they have are 
developmentally plastic; they have the ability to become many cell types when given the right 
extracellular cues.  Adult organs are mostly comprised of differentiated cells, however quiescent 
progenitor stem cells that have biological roles in physiological and pathological regeneration 
are found in discrete locations, or in systemic circulation. Identification of committed stem or 
progenitor cells has been done from various tissue sources, some of which include 
hematopoietic stem cells present in bone marrow [49], central nervous system stem cells from 
brain [50] ,skeletal muscle satellite cells [51] , and connective tissue mesenchymal stem cells 
[52]. Adult stem cells regenerate tissue by generating new populations of cells from progenitors. 
Several experiments showing the differentiation potential for adult stem cell populations 
have given rise to increased interest in their use in therapeutic applications. With their potential 
also comes controversy, as they have limitations such as reaching replicative senescence [53], 
Figure 1.2 iPSC uses for cellular therapy 
iPSC as autologous cell therapy through isolation of skin fibroblasts, reprogramming into induced 
pluripotent stem cells, and then differentiated into cell lineages useful for therapeutic application. 
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they vary in differentiation potential based on the derivation source [52] and in some cases have 
been demonstrated an inability incorporate into host tissues [54]. 
1.2.3 Trans-differentiated adult somatic cells- crossing lineage boundaries 
The direct reprogramming of one somatic cell to another somatic cell type is known as 
trans-differentiation. This has been demonstrated in a limited number of cases, with varying 
success rates. The general principle was founded out of iPSC work where it was hypothesized 
that if a fibroblast could be reprogrammed to a pluripotent cell, it may be able to cross lineage 
boundaries by forced transcription factor expression. It has been demonstrated that by either 
addition or ablation of specific transcription factors, in combination with cytokines and growth 
conditions, somatic cell sources can cross lineages into other somatic cell types. Fibroblasts 
have been shown to be directly convert to neurons by expressing neuronal lineage specific 
transcription factors in vitro [55]. Fibroblasts directly reprogrammed into blood progenitors by 
expression of hematopoietic transcription factors and a cocktail of cytokines have been shown 
to have functional engraftment in vitro [56]. While this approach holds potential, the need for 
forced transgene expression still harbors the same limitations as iPSC technology, and directly 
limits the clinical relevance of these trans-differentiated cell sources. 
1.2.4 Differentiated somatic cells – connective tissue fibroblasts 
The forced expression of genes to create cells for therapeutic purposes results in cells 
that are not therapeutically relevant.  Therefore, identification of cell culture conditions, which 
are able to induce endogenous expression of these genes required for either iPSC or trans-
differentiation, is critical for cell therapy. It has been demonstrated that fibroblasts have basal 
expression of mRNAs for stem cell genes, however the translation of these messages into 
properly localized proteins can be achieved by manipulation of oxygen concentration and FGF2 
supplementation. This change in culture conditions was shown to induce expression of REX1, 
potentiate the expression of LIN28 transcriptionally, and translationally induce expression of 
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nuclear OCT4, SOX2, and NANOG. Culturing human dermal fibroblasts under these defined 
conditions increased the lifespan in vitro, however these cells were not truly pluripotent, as they 
never formed tumors in SCID mice [57].  
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1.3 Regenerative Medicine—Search for a mechanism 
After the initial demonstration that somatic cells could be reprogrammed to pluripotency 
by defined factors [33, 34] studying the molecular mechanism of turning a somatic cell into a 
pluripotent cell was of high interest. Global studies looked at changes in the epigenetic state, as 
well as transcriptional changes throughout the reprogramming process.  
1.3.1 Mesenchymal-to-Epithelial Transition 
The first data to start to define this transition was a microarray data set, which looked at  
various time points within the reprogramming of MEFS [58]. This study showed that the 
immediate response to reprograming factors was increased proliferation [58].  
Figure 1.3 Mesenchymal-to-Epithelial Transition required for Reprogramming 
When studying either gene expression profiles or morphological changes of MEFs during the initial 
stages of reprogramming to iPSC there were similarities to MET. This pattern included the up-regulation 
of epithelial genes as well as the down-regulation of key mesenchymal genes. Based on the observed 
gene expression dynamics three sequential phases of reprogramming were identified [58]. 
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Subsequent microarray data, looking at the RNA-seq as well as RNAi screens, identified that 
fibroblasts undergoing reprogramming by defined factors go through three phases of 
reprogramming. These phases were termed by Li, et al. as (1) initiation, (2) maturation and (3) 
stabilization. Molecular events, which were identified and separated into these three phases, 
identified that a mesenchymal-to-epithelial transition was necessary within the initiation phase 
for cells to undergo reprogramming to a de-differentiated, induced pluripotent state [59, 60]. 
When studying late maturation phases of iPSC, it should be noted that transgenes required to 
drive reprogramming initiating events, and MET events are no longer necessary, however it is 
hypothesized that this is because genes involved in gametogenesis were up-regulated [61] 
(Figure 1.3). MET is dependent on expression of pluripotency transcription factors, and has 
been identified as the initiation step in acquisition of pluripotency through inhibition studies 
resulting in failure to induce pluripotency [59, 62].  
In order to understand the functional requirement for MET in iPSC induction, the process 
by which MET and EMT occur in development is critical. The epithelial-to-mesenchymal 
transition (EMT), and the reverse mesenchymal-to-epithelial transition (MET), have central roles 
in embryogenesis [63] (Figure 1.4). Most adult tissues and organs are formed through a series 
of a highly organized conversions of epithelial cells to mesenchymal cells through EMT and 
MET.  
Figure 1.4 Mesenchymal-to-Epithelial Transition 
Mesenchymal-to-Epithelial Transition (MET) is marked by the transition of a mobile 
mesenchymal cell to a polarized epithelial cell. The above schematic shows the transition from 
a mesenchymal phenotype to an epithelial phenotype via MET. Transition is marked by loss of 
mesenchymal markers and gain of epithelial markers. 
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Most critically, epithelial and mesenchymal cell phenotypes are reversible, and during 
embryonic development, cells can convert between the epithelial and mesenchymal states. 
EMT and MET conceptually were first defined by Elizabeth Hay 40 years ago [64]. Using the 
chick primitive streak as a model, Hay observed that epithelial cells were able to undergo a 
phenotypic changes that reflected a transformation to a mesenchymal cell (EMT) [64]. These 
events were subsequently observed in the reverse order (MET) [65, 66]. For the purposes of 
understanding the molecular events involved in cell phenotype conversion, it is necessary to 
understand MET.  
Mesenchymal cells are loosely organized in a three-dimensional extracellular matrix, and 
comprise connective tissues adjacent to epithelia. The conversion of mesenchymal cells to 
epithelial cells is observed in embryonic development and involves phenotypic changes defined 
by the acquisition of cell-cell adhesion and cell-cell polarity and the loss of migratory phenotype. 
In early embryonic development, mesoderm is generated by EMT, which forms multiple 
developmental tissue types. Examples include mesodermal cells generating epithelial organs, 
such as the kidneys and ovary through a series of MET [67]. 
1.3.2 FGF2: a diverse potent signaling molecule 
FGF2 is a vital growth factor involved in stem cell determination in vitro [47, 68]. In 
humans, FGF2 is produced as five isoforms (18, 22, 22.5, 24 and 34 kDa), which have different 
subcellular localizations and contribute to different cellular behaviors [69, 70]. FGF2 isoforms 
are generated by alternative initiation of translation of the same FGF2 mRNA [71]. The 18 kDa 
FGF2, termed low-molecular weight (LMW), is translated from a conventional Kozak [72] AUG 
start codon and consists of 155 amino acids, which represents the core sequence common to 
all FGF2 isoforms [73]. The additional four FGF2 isoforms are known as high-molecular weight 
isoforms, and are initiated by upstream CUG sites [74, 75]. LMW FGF2 signaling through FGF 
receptors (FGFRs) has roles in development in the adult such as, tissue repair, angiogenesis, 
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wound healing, and inflammatory response [69]. FGFR pathway disruption has been linked to 
many disease pathologies, including cancer [76, 77].  
FGFRs are receptor tyrosine kinases structurally composed of an extracellular ligand-
binding domain linked by a single transmembrane domain to the intracellular protein. FGFRs 
are activated in a ligand-dependent manor leading to receptor dimerization [78] that results in 
activation of the kinase domain, and signaling through the mitogen-activated protein kinase 
(MAPK) pathway. Dimerization and activation of FGFRs can also activate PI3K, PLCγ and 
signal transducers and activators of transcription. Examples of downstream effects of FGF2 
signaling include proliferation, growth, differentiation, migration, and survival [69, 79].   
The predominant signaling pathway activated downstream of FGFRs is MAPK signaling 
which has roles in both development [80] as well as cell proliferation by promoting cells to enter 
S-phase through activating expression of cyclin-D1 [81]. MAP kinases are a family of proteins 
that have a variety of cellular roles: ERK1/2 is known to be a regulation of mitosis; JNK1/2/3 is 
known to be involved in stress-activated inhibition of protein synthesis; and p38α/β/γ/δ are 
known to regulate expression of inflammatory cytokines [82].  
1.3.3 Stem Cell Niche as a requirement for maintenance of potency 
In order to maintain potency, human embryonic stem cells are dependent on growth in 
colonies which are highly adherent [31] and addition to attachment, human embryonic stem 
cells are dependent on the addition of basic fibroblast growth factor 2 (FGF2), from either 
exogenous supplementation, or mouse embryonic fibroblast conditioned culture medium [46, 
47]. 
Just as attachment of hESC is known to play a role in maintenance of pluripotency, a 
specialized niche is important for phenotype maintenance of adult stem cells. Adult stem cells 
are responsible for the growth, maintenance and overall homeostasis of most adult tissue types 
within the body. The survival and maintenance of multipotency is regulated by the 
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microenvironment in which they reside [83]. This microenvironment, otherwise known as niche, 
is defined as an anatomical compartment which signals to the cell in the form of secreted and 
cell surface molecules that are critical in the control of many processes, including the rate of 
proliferation, and developmental fate of the daughter cells [84].  Early experiments in worms and 
flies provided the first visualization of the stem cell niche in vivo, and subsequent experiments 
within these systems confirmed the necessity of the niche in regulation of stem cell fate. 
Figure 1.5 Stem Cell Niche Composition 
Composition of the niche. Stem cell niches are complex and dynamic structures, which include 
different, environmentally modulated molecular controls, some of which are secreted factors, 
physical interaction with ECM, and oxygen concentration.  
Figure adapted from Watt et al., 2014. 
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to be just as important as in the early models systems. Each adult stem cell has its own 
dynamic and independently complex niche [85, 86]. These distinct niches provide support for 
each stem cell type within the body. The niche can be defined as a subset of tissue, cells, and 
extracellular substrates that provide support, and can indefinitely house stem cells. In addition to 
being a home, this niche provides the cues that provide the ability for the stem cell to remain 
undifferentiated indefinitely (Figure 1.5).  
It has also been described that stem cells in normal tissues are capable of self renewal 
through asymmetrical cell division, while simultaneously generating committed progenitor cells 
whose descendants may eventually differentiate and carry out tissue specific functions [87]. Of 
more recent importance, a study of neoplastic tissues has provided evidence of self-renewing, 
stem-like cells within tumors named cancer stem cells (CSCs). CSCs constitute a small minority 
of neoplastic cells within a tumor, and are defined by their ability to act as tumor initialing cells 
and are thought to be supported through discrete niches within tumors [87].  
In mammalian tissues, stem cell niches have started to be characterized and are thought 
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1.4 Role of Extracellular Matrix and Attachment, necessary for engraftment 
The biology of the extracellular matrix (ECM) has grown of interest recently due to the 
increasing body of literature in support of ECM as a means to support stem cell self-renewal 
through niche mediated biological signaling cascades [48]. These support mechanisms include 
but are not limited to harboring growth factors, and the support of three-dimensional structure. 
The field of tissue engineering focuses on creating 3D tissues, which facilitate cell growth, 
proper organization and subsequent differentiation. Therapeutic applications for 3D biology as a 
means to regenerative medicine holds much promise, however, arguably there is a long, 
strenuous road from bench-to-bedside. In order to begin to make these transitions, current 
signaling biology must be transitioned from 2D to 3D applications, as 3D cell culture provides a 
necessary feature which allows for mechanical stimulation which is heavily involved in cellular 
adhesion such as integrin ligation, cell contraction and associated signaling cascades [88]. 
ECM, integrins, and growth factors as components of cellular niche have many demonstrated 
roles cell biology, stem cell self-renewal, and matrix specific regulation of cell fate [89].  
1.4.1 Integrins as mediators of tissue-specific engraftment 
Use of pluripotent-derived cells as therapeutics in regenerative medicine is dependent 
on their efficiency of integrating within existing tissue, which includes other cells and 
extracellular matrix components [90, 91]. Tissues and organs have specific architectural and 
molecular compositions in which cells reside. Engraftable cells will need to rebuild functional 
tissue architecture in the presence of the existing ECM and cells. Most recent attempts have 
resulted in disappointing outcomes, as clinical data from a skeletal muscle myoblast study [92] 
and bone marrow mononuclear cells for myocardial repair [93] have shown that more work 
needs to be done towards understanding what controls engraftment, and what lineages are 
necessary [94].  
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Although some successful observations have been made in engrafting cells in 
hematopoietic systems [95], this success may not necessarily apply to solid organs. Several 
other reports have provided exciting proof-of-principle evidence that the seeding of de-
cellularized tissue scaffolds with endothelial and epithelial cells grown in bioreactors can 
produce bio-artificial lungs [96, 97], livers [98], and hearts [99] that engraft in animals and exhibit 
normal tissue function for up to several days. 
Survival of transplanted cells is of vital importance when considering the use of cells as 
therapeutics in regenerative medicine, and cellular integrins are the major mediators of cell 
adhesion and are responsible for activating cell survival by preventing apoptosis [100]. Integrin-
mediated cell signaling activates PI3K and AKT, which ultimately regulate cyclin-D to regulate 
DNA synthesis, among other cellular functions [101]. The repertoire of integrins and ECM 
binding is cell-type and tissue-type dependent. Functional homing of cells require interactions of 
a varying range and diversity of ECM ligands with integrin pairs to mediate tissue specific, 
proper homing.  Cells can require multiple attachment integrins as demonstrated by the 
example of liver sinusoidal endothelial cells which require α6β1, α6β4, αVβ3, αVβ6 and αVβ5 
and bind multiple ECM ligands [102], or a very finite number of attachment points, while 
hepatocytes require α2β1 and α5β1 binding to collagen and fibronectin [103].  
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1.5 Extracellular Matrix 
In order to understand the cytoskeleton, cell migration, cell growth, cell fate and 
differentiation it is necessary to understand the structure and the biology of the extracellular 
matrix (ECM) as well as its composition.  A simple definition for the ECM is that it is a structural 
material that lies under the epithelia and surrounds connective tissue cells [104]. However, it is 
no longer thought that the ECM is just a support system for the cells that interact with it. Cells 
have relationships regarding fate to the ECM they create, and the ECM created by the cells 
surrounding them [105, 106].  
The main characteristic that defines ECM regardless of location is the basic structure, 
which contains a collagen-based scaffold, however the type of collagen, which makes up each 
tissue specific ECM is different. Adhesive glycoproteins (i.e. laminin and tenascin) adhere to this 
collagen scaffold and interact with the cells adjacent to the matrix. Interactions between cells 
and matrix are facilitated by integrins, and ECM is not static, it is constantly undergoing 
breakdown by matrix metalloproteases [107].  
1.5.1 Collagens 
Collagens are ubiquitous proteins responsible for maintaining the structural integrity of 
vertebrates and many other organisms [108]. More than 20 distinct collagens have been 
identified [109-112]. In tissues that need the ability to resist shear, tensile, or pressure forces, 
such as tendons, bone, cartilage, and skin, collagen is arranged in fibrils that provide tensile 
strength. Collagen types I, II, III, V, and XI self-assemble into fibrils [110]. Type IV, VIII and X 
collagen form networks such as the collagen found in basement membranes [113], and type VI, 
IX, XII and XIV collagens associate with fibril surfaces collagen [114].  Collagens type XIII and 
XVIII are more rare, and are transmembrane, and type VI forms a braided structure [110].  
Type I collagen occurs throughout the body, except in cartilage. It is the major collagen 
in the dermis, fasciae, and tendons and is the largest component of mature scar tissue [115]. 
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Type II collagen occurs in cartilage, the developing cornea, and in the vitreous body of the eye 
[116]. Type III collagen dominates in the wall of blood vessels and hollow intestinal organs, and 
copolymerizes with type I collagen [117].  
1.5.2 Laminin 
Laminin, in conjunction with collagen type IV, nidogen, and perlecan, is a major 
contributing component of basement membrane [118, 119]. The primary role for laminin seems 
to be mediation of the interaction between cells and the extracellular matrix, notably the 
basement membrane [118]. Laminin's consist of three disulphide linked chains, and form a 
characteristic cross shape. To date, five α chains, three β chains and three γ chains have been 
identified [120]. Of the chain combinations possible, all have not been identified in tissues.  
1.5.3 Proteoglycans 
Proteoglycans can be grouped into several families which all have a protein core which 
is surrounded by glycosaminoglycan [121]. The function of proteoglycans was originally 
assumed to be only structural, as a mechanism to provide protection against compression 
through mediating rigidity as a structural feature [122], however a member of the proteoglycan 
family, versican, has roles in addition to just being a structural component and has been shown 
to stimulate the proliferation of fibroblasts and chondrocytes through its EGF-like motifs [123]. 
Additionally members of the proteoglycan family are characterized by a protein core which is 
composed of leucine rich repeats [121, 124] which were first thought to act as facilitators to 
organization of collagen networks, however it has recently been demonstrated that decorin is 
involved in signal transduction through the EGF receptor and downstream signaling through the 
MAPK pathway [125, 126].  
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1.3.5.1 Heparan sulphate proteoglycans 
Heparan sulphate proteoglycans are matrix proteoglycans that are membrane-
associated and are predominantly found in basement membranes. FGF ligands are involved 
with low affinity co-receptors including heparin and heparan sulfate proteoglycans [127-130]. 
FGF and FGF receptors can bind heparan sulfate proteoglycans, and it is thought that heparan 
sulfate proteoglycans can act to bind FGF to the receptor to facilitate subsequent signaling [128, 
131-134].  
1.5.4 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases [135]. 
There are 23 distinct MMPs expressed in humans, all of which have a general structure of three 
common domains, and MMPs are subsequently characterized by their architectural features 
MMP [136, 137]. Fibroblasts express MMP1-3, 9, 11, 13, and 19 [138]. MMPs play a role in 
various physiological processes including tissue remodeling and organ development [139], in 
the regulation of inflammatory processes [140] and in diseases such as cancer [141].  
1.6 Integrins: 
As a family, integrins were first recognized over 25 years ago [142]. They have been 
identified and restricted to the metazoa, with no homologs present or predicted in plants or fungi 
[143]. Even within the most primitive metazoan, integrins are present as heterodimers [144, 
145]. 
Integrins have been studied and identified for biological roles as adhesion receptors, 
mediators of development [144], immune response, and leukocyte trafficking, cancer as well as 
cancer metastasis [145, 146]. Integrins are a large family of heterodimeric, transmembrane cell 
surface molecules, which serve as the main receptors for extracellular matrix [100].  Functional 
integrin receptors consist of an alpha (α) and a beta (β) subunit which dimerize to form 
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functional heterodimeric receptors [147, 148], interact with ECM, and generate intracellular 
signal transduction [100]. Integrin receptors are expressed in many cell types and play critical 
roles in a diverse range of biological processes including cell motility, adhesion, proliferation, 
apoptosis, development and inflammation (Figure 1.6). 
Figure 1.6 Integrins are Bidirectional Signaling Molecules 
Upon ligand binding to integrin receptors, focal adhesion kinase pathway can become 
activated, and this can have several downstream effects through activating or repressive actions 
of transcription factors. They can (a) cause inhibition of integrin ligand binding, (b) alter the 
expression of differential integrins and extracellular matrix and (c) induce extracellular matrix 
proteolysis.  
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Figure 1.7 Integrin alpha and beta pairs and associated receptors 
This figure is depicting alpha and beta integrin subunit pairs. Out of the 8 beta 
subunits, they can pair with 18-alpha subunits to form 24 distinct integrin receptors 
which each have different extracellular matrix affinities which is depicted here by 
groupings.  
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Within vertebrates, 18-alpha (α) and 8-beta (β) integrin subunits have been identified, 
which can heterodimerize to form 24 distinct αβ pairs (Figure 1.7). These αβ pairs connect to 
either the actin cytoskeleton or to intermediate filaments.  Integrin adhesiveness is dynamically 
regulated and modulated through ‘inside out’ signaling such that signals that are received 
outside the cell can be processed intracellularly, and vice-versa (Figure 1.6).  Extracellular 
stimuli, such as chemokines, cytokines, and foreign antigens can activate ‘inside out’ signaling, 
and modulate integrin cytoplasmic domains, and subsequent signaling, as well as modulate 
adhesiveness for extracellular ligands [104, 149, 150].  
Both the α and the β subunits of integrins are type I transmembrane glycoproteins with 
large extracellular domains and single spanning transmembrane domains. Electron microscopy 
has demonstrated that integrins contain an extracellular globular N-terminal ligand-binding 
domain, which is necessary for the interaction between the α and β subunits [100, 151]. αvβ3 
was the first to have an X-ray crystal structure identified, and it was shown that the integrin had 
‘legs’ severely bent at the ‘genu’ or knee, which could create a V-shaped topology, where the 
head domain was juxtaposed to the membrane proximal region [152, 153]. This discovery was 
defined as integrin resting, and a large number of integrin subunits have been described to 
exhibit a conformational change this way as well. This bent confirmation has been determined to 
represent a physiologically low affinity state [152], where activation allowing for rearrangement. 
Integrins can also change conformational state, resulting in the extension of the head region, 
and subsequent binding of the extracellular ligand [154, 155] (Figure 1.8). 
In addition to different activation states, different integrin pairs have been shown to 
regulate ECM composition differentially. α1 has been shown to stimulate proliferation in cells 
[156] and decrease collagen production [157, 158], while α2 has been demonstrated to increase 
both collagen production and turnover [157-160]. 
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Adhesions mediated by integrins are assembled from a complex family defined by a 
diverse and elaborate network of structural and molecular regulatory roles. This complex family 
of regulation is known as the integrin adhesome [161]. This adhesome consists of over 232 
components, which can be categorically divided into 148 components which are present directly 
at the site of adhesion, and another 84 components which can be transiently associated with the 
adhesion and subsequently its signaling [162]. This large dynamic and complex system is still 
poorly understood. 
Figure 1.8 Integrin alpha and beta structure 
Integrin alpha and beta linear domain structures and integrin dimer structure as an activated 
dimer. Ligand binding occurs at the Beta-propeller region and Beta-1 domain. 
27 
 1.7 Integrin- alpha 11 
Integrin α11 is the most recent member of the integrin family to be discovered. α11 was 
identified on cultured human fetal myotubes in vitro [163]. Additionally a mouse variant has been 
identified [163]. In muscle, α11 is not present in vivo, and expression of α11 has been shown in 
vivo to be through fibroblasts present in native muscle architecture [164]. α11 is an integrin 
beta-1 pairing integrin, and as a heterodimer α11β1 binds collagen type-I (COL-I) [165]. α11β1 
attachment to COL-I has high affinity for COL-I, and low affinity for collagen-IV through co-
transfection studies with varying integrin alpha subunits in mouse muscle satellite cells [166- 
168]. The I domain of α11 recognizes the triple-helical conventional GFOGER motif sequence 
present in collagen-I [166]. Functionally, α11 has been shown to be involved in cell migration 
and collagen reorganization [169]. 
The human α11 gene (ITGA11) is localized on chromosome 15q23 and spans 130kb. 
Both the human and mouse ITGA11 gene contain 29 introns (Figure 1.9). Human ITGA11 
promoter lacks both TATA and CCAAG boxes [167], and the transcription start site is 30 
nucleotides upstream of ATG [170]. Promoters of Integrin-α subunits contain conserved initiator 
elements generally associated with an upstream Sp1 site proximal to the transcription start site 
[171], which is thought to be necessary for expression due to lack of a TATA box. An Sp1 
binding site lies within ITGA11 upstream of the putative initiator sequence. An Sp1 and an Ets-1 
site in the proximal promoter of ITGA11 has been shown to be essential for its promoter activity 
[167] through a screen of promoter deletion constructs which characterized the 3kb region that 
has been found to have a high level of transcription activity.  
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Figure 1.9: Integrin alpha-11 structure 
This figure defines the overall structure of integrin alpha 11. (a) schematic overview of ITGA11 
gene which is 130 kb located on chromosome 15q23, and contains 30 exons, (b) schematic 
overview of α11 protein, I-domian – I-d, 7-FG-GAP repeats making the β-propeller, calf-1 and 
calf-2 – C1, C2 respectively, transmembrane domain – TM and cytoplasmic tail – CT. (c) 
schematic representation of straightened active conformation of α11 protein with domain 
structures based on crystal structure of αv integrin, with the I-domain located  between the 
second and third β-propeller repeats.  
ITGA11 encodes a mature protein of 1166 amino acids which under reducing, and 
denaturing conditions runs at 145kD. The extracellular domain contains seven FG-GAP repeats 
and a 195-amino acid-long I domain inserted between the repeats 2 and 3. The I domain 
presents a metal ion-dependent adhesion site (MIDAS) motif and three potential divalent cation 
binding motifs. The cytoplasmic tail contains 24 amino acids, and contains a GFFRS motif, 
which is different than the GFFKR motif that is commonly found in alpha subunits. Human and 
mouse a11 integrin chain shows 89% identity and 97% identity, respectively, within the I domain 
[172, 173]. 
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In human adult tissue, the α11 transcript is expressed in high levels in uterus and heart 
and at midrange levels in skeletal muscle [174]. The α11 chain expression is described as being 
specific to mesenchymal non-muscle cells in vivo, but a complete characterization in adult 
tissues has not yet been performed [175].  As a Col-I binding integrin, α11 shows high levels of 
expression in more restricted cell types in comparison to other collagen-interacting alpha 
subunits, as α1 and α2 have been shown to be expressed in a wider array of cells types [176, 
177]. 
1.7.1 Integrin alpha-11 Regulation 
Cytokines regulate α11 expression due to TGF-β1 responsiveness in Smad2/3 and Sp1-
regulated transcription. The ITGA11 proximal promoter contains Smad-binding element SBE2 
and the Sp1-binding site SBS1 (Figure 1.10). In transgenic reporter mouse embryos, the human 
3kb ITGA11 promoter drives a fibroblast-specific expression [170]. TGF-β1 has been 
demonstrated to up-regulate α11 in a fibrosarcoma cell line (HT1080), in human dermal 
fibroblasts [178] and fibroblasts (MRC-5) [164, 179]. TGF-β superfamily member Activin-A has 
also been shown to be a mediator of α11 up-regulation when added to mouse embryonic 
fibroblasts (MEFs) [170]. IFNs have been shown to stimulate α11 transcription and translation 
[180, 181]. Type-I interferons, including IFNα and IFNβ, have been shown to regulate α11 
expression in a human glioblastoma cell line (T98G).  Down-regulation of a11 has been reported 
to occur in mesenchymal stem cells and mouse embryonic fibroblasts treated with FGF2 [182, 
183]. However, the responsive elements involved in this down-regulation have not yet been 
determined in the α11 promoter [175].  
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Figure 1.10 Integrin alpha 11 promoter 
Figure from Lu et. al., 2010. Integrin alpha-11 human and mouse promoters aligned and 
mapped. Smad binding elements indicated as SBE1 and SBE2, Ets-binding site (EBS) and 
transcriptional start site (TSS).   
1.7.2 Integrin alpha-11: Function 
In vivo functionality of α11 has been shown using a α11-deficient knockout mouse 
model. α11-deficient mice are smaller and have an increased rate of mortality when compared 
to heterozygous knockouts or wild-type mice [174]. The smaller size of α11-deficient mice 
appears to be linked to malnutrition as a result of late incisor eruption and abnormal tooth 
shape. This hypothesis is further strengthened by the observation that bone formation and 
development of connective tissue appear normal, and in addition α11 is expressed in in vivo at 
sites where collagens are highly organized [184]. As demonstrated in knockout mouse models, 
high expression of α11 has been demonstrated in the periodontal ligament [163, 178, 182]. 
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Most recently α11 has also been reported in tumor tissue from melanoma and lung 
carcinoma [185], and cancer-associated fibroblasts contribute high levels of α11 expression in 
lung carcinoma. In addition to lung cancer, α11 in a xenograft model α11 was shown to enhance 
tumorigenicity by up-regulating IGF-2 expression [185]. Yet the role of α11 in cancer-
associated-fibroblasts, as well as their role in TGF-β1-dependent myofibroblast differentiation in 
tumor stroma during subsequent growth and metastasis is unknown.  
The detailed molecular mechanism involved in α11β1 function is not well known. This 
includes the major signaling pathways utilized by α11β1 and its involvement in various 
pathological conditions and little is known about its role in the MET transition. Further studies of 
the α11 regulation will be imperative to determine how α11 expression is controlled in 
fibroblasts, myofibroblasts and cancer-associated-fibroblasts. It is necessary to elucidate the 
response of ITGA11 to growth factors such as FGF2 and TGF-β1 as they are and mediators of 
fibrotic program, and potential therapeutic targets for adverse fibrotic response such as solid 
tumor stroma.  
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1.8 Summary of Thesis 
The work contained in the succeeding chapters of this thesis extends the observations 
published by our laboratory, showing that relatively simple manipulation of cell culture 
environment in vitro can lead to significant changes in the gene expression profile of human 
dermal fibroblasts (hDF). These cells activate expression of stem cell genes (Oct4, Sox2, 
Nanog, Rex1 and Lin28), demonstrate increased life span in vitro, and acquire regeneration 
competence (induced regeneration competent cells - iRC). The culture system mediating these 
changes is characterized by reduced oxygen tension and the addition of exogenous fibroblast 
growth factor FGF2.  While iRC cells exhibit some molecular characteristics of pluripotent cells 
they do not acquire pluripotency and they do not form tumors when injected into SCID mice. 
One major characteristic of our in vitro culture system is the induction of an extended lifespan. 
In addition, human muscle derived fibroblasts cultured under the aforementioned conditions 
contribute to regeneration of mouse skeletal muscle through functional engraftment and 
acquisition of a PAX7 positive satellite stem cell phenotype. FGF2 appears to be the critical 
component to this system.  
To further characterize how low oxygen-mediated FGF2 affects human fibroblasts, we 
investigated molecular mechanisms involved in altered expression and production of 
extracellular matrix and adhesion molecules, and the role of these changes in phenotype 
switching. 
Objective 1 
Characterize extracellular matrix and adhesion molecule shifts in human dermal 
fibroblasts (hDF) undergoing a phenotype shift resulting in induced regeneration 
competent phenotype (iRC) 
In this chapter we test the hypothesis that FGF2 signaling under low oxygen conditions 
induces changes in the expression of extracellular matrix and adhesion molecules that 
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reflect the transition in their developmental potential – namely, a departure from 
producing predominantly a collagen-based environment. 
A large number of molecular cues that cells receive in vivo are through their extracellular 
niche, therefore we hypothesize that the role of the extracellular environment on cell behavior in 
vitro is equally critical for induction and maintenance of shifting the cells’ developmental 
potential. We identify an overall deregulation of extracellular matrix (ECM) and adhesion 
molecules (AM) in human dermal fibroblasts grown in low oxygen with FGF2 supplementation 
(iRC). An ECM/AM microarray was used as an initial screen, and we identify 15 most 
significantly deregulated genes and confirmed their deregulation by qRT-PCR. From the 15 
targets chosen, we characterized iRC by a change in niche dynamics defined by the most highly 
deregulated targets belonging to a similar ontology.  A 17-fold down-regulation in Itga11 
(collagen-I attachment) and a 5-fold MMP1 (collagenase type-I) up-regulation led us to 
hypothesize that iRC cells were remodeling the extracellular niche by removing collagen-I and 
subsequently, producing and adhering to non-collagen-I based substrate. By Western blot we 
show a decrease in collagen COL-I from iRC cultures, as well as its binding integrin alpha-11. 
Additional qRT-PCR analyses for alternate integrin alpha and beta subunits identified 
expression of integrins that are preferential binding partners for RGD and laminin substrates, 
which are indicative of a niche with basement membrane components. 
Objective 2:  
Investigate the mechanism of low oxygen mediated-FGF2 effect on integrin alpha-11 
expression 
In this chapter we test the hypothesis that the low oxygen-mediated FGF2 signaling is 
suppressing the transcriptional activity of integrin α11 either directly or indirectly.  
Deposition of collagen-based extracellular matrix by fibroblasts during wound healing 
leads to scar formation, which is a typical outcome of the healing process in soft tissue wounds. 
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Increase in collagen production and increase in collagen binding adhesion molecules – integrins 
– regulated primarily through TGF-β1 signaling, which in turn is regulated by FGF2. In this
chapter we investigate the mechanism of a collagen-I-binding integrin α11 (ITGA11) down-
regulation in response to low oxygen-mediated FGF2 activity. Using RT-PCR, qRT-PCR, 
Western blotting and immunocytochemistry, we describe significant down-regulation of ITGA11. 
We show that loss of ITGA11 requires FGF2 induced ERK1/2 activity, and in the presence of 
FGF2, ITGA11 expression cannot be rescued by TGF-β1, a potent activator of ITGA11. These 
results indicate that the ERK1/2 mediated FGF2 down-regulates α11 by suppressing TGF-β1 
activity. Additionally, we show that FGF2 is capable of overriding TGF-β1 mediated alpha-
smooth muscle actin expression, a marker of pro-fibrotic activated fibroblasts.  
Objective 3 
Determine if acquisition of induced regeneration competent phenotype in human dermal 
fibroblasts proceeds through the Mesenchymal to Epithelial Transition (MET), and 
whether this transition is modulated by integrin alpha-11 
In this chapter we hypothesize that the transition between a fibroblast and an induced 
regeneration competent cell proceeds through a mesenchymal-to-epithelial transition 
(MET), and that this transition is a consequence of down-regulation of α11. 
In this chapter we characterize the presence of focal adhesions and focal adhesion 
kinase activity in iRC’s, and identify the activation of initiation stage MET genes. These 
observations indicate that the activation of MET initiation stages may require a shift in 
extracellular matrix and adhesion molecules. We attempt to confirm a regulatory role for α11 in 
this transition, but cannot achieve over-expression of α11. Similarly, knock-down studies of α11 
through transient transfection remain inconclusive. To facilitate MET, we aggregate and 
subsequently culture iRC’s in 3D aggregates. We show by Western blot and immunostaining 
that aggregates do not express epithelial cadherin, which is a defining marker for epithelial 
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phenotype. We argue that while the completion of MET with acquisition of an epithelial 
phenotype is necessary for induction of pluripotency, understanding the mechanism of a partial 
transition may lead to development of cell phenotypes for therapy without the associated risk of 
tumor formation.  
Thesis Conclusions 
This thesis describes an overall shift in extracellular matrix and adhesion molecules in 
human dermal fibroblasts undergoing the initiation phase of Mesenchymal to Epithelial 
Transition during conversion to induced Regeneration Competent cell phenotype. This transition 
is marked by a loss of α11 and its binding partner Collagen-I by a mechanism that is mediated 
by ERK1/2 activation and suppression of TGF-β1 mediated regulation of α11. Additionally, a 
shift in the transcript levels of other adhesion molecules demonstrate that iRC are most likely 
transitioning to attachment to a laminin and fibronectin-based matrix, suggesting that they may 
be producing a more “pro-regenerative matrix”. We hypothesize that the shift in cells production 
and interaction with ECM serves as a feedback loop during the phenotype shift, as contact with 
extracellular matrix and its involvement in the regulation of potency in adult stem cells within the 
niche has been demonstrated extensively. We also hypothesize that this “pro-regenerative” shift 
can be exploited in wound healing biology, as it triggers a non-fibrotic response in dermal 
fibroblasts, overriding TGF-β1-mediated fibrotic response. As both, TGF-β1 and FGF2 are 
present at the wound site, manipulation of the dynamic relationship between the two could be 
used to reduce scar deposition. 
In summary, our cell culture system allows for a cell-fate conversion from an abundant 
adult differentiated cell source to a more ‘developmental’ plastic cell type. This cell phenotype 
has a potential for therapeutic applications in regenerative medicine. Identification of molecular 
mechanisms controlling this phenotype conversion will allow development of strategies for in 
situ manipulation of wound healing outcomes.  
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Chapter 2 
Characterization of Extracellular Matrix and Adhesion 
Molecules in Human Dermal Fibroblasts Undergoing Induced 
Regeneration Competence 
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2.0 Abstract 
A large number of molecular cues that cells receive in vivo are through their extracellular 
niche, therefore we hypothesize that the role of the extracellular environment on cell 
behavior in vitro is equally critical for induction and maintenance of cells which are 
shifting their developmental potential. In this chapter we identify an overall deregulation of 
the extracellular matrix (ECM) and adhesion molecules (AM) that accompanies an extended 
lifespan phenotype in human dermal fibroblasts grown in low oxygen with FGF2 
supplementation, that we have named induced regeneration competence (iRC). An ECM/AM 
microarray was used as an initial screen that identified the 15 most significantly deregulated 
genes, and confirmed their deregulation by qRT-PCR. We characterized iRC by a change in 
niche dynamics defined by the most highly deregulated targets belonging to a similar ontology. 
A 17-fold down-regulation in Itga11 (collagen-I attachment) and a 5-fold MMP1 (collagenase 
type-I) up-regulation led us to hypothesize that iRC cells were remodeling the extracellular niche 
by degrading collagen-I and subsequently producing and adhering to non-collagen-I based 
substrate. Western blot analysis  showed a decrease in collagen-I (COLI) protein in iRC 
cultures, as well as a decrease in its binding integrin alpha-11. Additional qRT-PCR analyses for 
alternate integrin alpha and beta subunits identified up-regulation in expression of integrins that 
are preferential binding partners for RGD and laminin substrates, which were indicative of a 
niche comprised of basement membrane components. 
Objectives and Hypothesis 
The objectives of this aim were to 1) characterize the changes in expression of 
extracellular matrix and adhesion molecules in human dermal fibroblasts (hDF) undergoing a 
phenotype shift resulting in induced regeneration competent phenotype fibroblasts (iRC), and 2) 
test the hypothesis that FGF2 signaling under low oxygen conditions induces changes in the 
expression of extracellular matrix and adhesion molecules that reflect the transition in their 
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developmental potential – namely, a departure from producing predominantly collagen-based 
environment. 
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2.1 Introduction 
Regenerative medicine has been receiving an increasing amount of attention over recent 
years due to the clinical and commercial potential. The successful derivation of human 
embryonic stem cells (hESC) was groundbreaking [1], however hESC have limitations in their 
potential for therapeutic application as they are a non-autologous cell source and they have 
raised ethical debates in relation to their source and subsequent derivation [2]. The 
development of induced pluripotent stem cells (iPSC) [3, 4] created the ability to derive a 
pluripotent cell from a somatic cell source, which in turn increased the momentum of 
regenerative medicine research. Research focus was able to shift to cell based applications 
because the potential range of applications for an autologous, pluripotent, cell source is far 
broader for cell therapy and disease modeling than hESC. 
The discovery of iPSC [5] led to a sustained effort from many research groups to try to 
develop novel derivation strategies. However, major hurdles still exist before iPSC-derived cell 
therapy can be used in patients. DNA-integrating viruses were first used to create iPSC, but this 
introduces genomic alterations deeming these cells non-clinically compliant [6]. Recent 
protocols achieve the reprogramming using non-integrative methods such as Sendai virus [7], 
non-integrating adeno-associated virus [8], episomal vectors [9], microRNAs, protein delivery 
[10] or PiggyBac transposons [11, 12]. This progress has eliminated the potential for virally 
induced tumor formation, and these methods are able to minimize genomic perturbations [13] 
however, iPSC derived with the aforementioned protocols all come with individual limitations 
[14]. A common limitation is that they all have low reprogramming efficiency.  
Interest and efforts so far have been focused on using exogenously added factors to 
induce cellular reprogramming, however the interest in methods for derivation and maintenance 
of stem cells has shifted its focus to the importance of environmental cues, with emphasis on 
the role of extracellular matrix (ECM) and adhesion molecules (AM) [15]. However in order to 
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use the potential of the environment to direct the cell-fate, it is necessary to understand the role 
of the extracellular environment on stem cell pluripotency, maintenance of pluripotency, and 
behavior.  It is well documented that one of the most critical proteins involved in the derivation, 
and maintenance of hES and iPSC is basic fibroblast growth factor (FGF2) [16-18], and its 
bioavailability and activity is mediated by the extracellular matrix proteoglycan, heparan sulfate 
[19-23]. 
During our work in cellular reprogramming, we have shown that relatively simple 
manipulation of the cell culture environment in vitro can lead to many changes in the gene 
expression profile of these cells [24]. Moreover, these changes result in an iRC phenotype 
which we define by the induction of expression of stem cell genes (Oct4, Sox2, Nanog, Rex1 
and Lin28) and an increase the life span of human dermal fibroblasts [25]. This culture system is 
characterized by reduced oxygen tension and the addition of exogenous FGF2.  Human dermal 
fibroblasts (hDF) cultured under those conditions exhibit some molecular characteristics of 
pluripotent cells; however they do not acquire pluripotency and do not form tumors when 
injected into SCID mice [25]. One major characteristic of our in vitro culture system is the 
induction of an extended lifespan. In addition, human muscle derived fibroblasts cultured under 
the aforementioned conditions contribute to regeneration of mouse skeletal muscle through 
functional engraftment and acquisition of a PAX7 positive satellite cell phenotype [26]. As with 
maintenance of pluripotency, FGF2 appears to be the critical component to our system.  
In humans, five FGF2 isoforms can be produced (18, 22, 22.5, 24 and 34 kDa), which 
display different subcellular localization and contribute to different cellular behaviors [27, 28]. 
The 18 kDa FGF2 isoform signals through ligand-dependent activation of it’s receptor tyrosine 
kinase family [29], and is the isoform used throughout our studies.  
Based on our previous data, we hypothesized that changes in the ECM and AM 
expression profile may play a role in the phenotypic shift of an hDF to an iRC, resulting in a 
niche that is permissive to a more plastic state. A large amount of the molecular cues that the 
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cells receive in vivo are through their extracellular niche [30], and the role of the extracellular 
niche on stem cell behavior in vitro is equally as critical for maintenance of pluripotency. Stem 
cells (adult and embryonic) reside in dynamic yet specialized microenvironments, which provide 
molecular cues that control the balance between self-renewal and differentiation [31-33]. 
Differential expression of extracellular matrix proteins serves to mediate the specificity of the 
stem cell to its niche [32, 34]. Extracellular matrix proteins are also involved in mediating homing 
to the niche and serve as a reservoir for growth factors and cytokines [35]. Molecular cues that 
are involved in maintenance of plasticity come from cell-cell contact, as well as cell-matrix 
contact [33, 36, 37]. Interplay between integrins and the niche are known to support tissue 
specific stem cells through the interaction of cadherins and integrins specifically [38].  
To support pluripotency of hESC and iPSC in vitro, it is known that in lieu of a feeder 
layer, murine basement membrane can support pluripotency. Classically, stem cell fate was 
thought to be controlled by genetic and molecular mechanisms, however we now know that the 
extracellular environment is arguably equally important in stem cell fate determination through 
ECM and AM. Integrins are responsible for transmitting extracellular cues through intracellular 
signaling [39]. 
A major contributor to the signaling from ECM / AM are integrins. Integrins are a large 
family of hetrodimeric, transmembrane cell surface molecules which serve as the main 
receptors for ECM [39]. Functional integrin receptors consist of one alpha (α) and one beta (β) 
subunits, which form biologically functional receptors [40, 41] that can interact with the ECM, 
and can result in the activation of intracellular signal transduction pathways [39]. Integrin 
receptors are expressed on many cell types and play critical roles in a diverse range of 
biological processes including cell migration, adhesion, proliferation, apoptosis, development, 
and inflammation [42]. Integrins are more than just cell adhesion molecules; they transmit bi-
directional signals across the plasma membrane [39]. Integrin adhesiveness is dynamically 
regulated and modulated through ‘inside out’ signaling such that signals that are received 
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outside the cell can be processed intracellularly, and vice-versa.  Extracellular stimuli such as, 
chemokines, cytokines, and foreign antigens can activate ‘inside out’ signaling, and modulate 
integrin cytoplasmic domains, and subsequent signaling, as well as modulate adhesiveness for 
extracellular ligands [43-45]. Due to the dynamic range of bi-directional signals that integrins 
can transmit, and the complexity of the system, much is yet to be discovered about what 
integrin signaling mediates.  
 This section of my thesis defines the overall changes in the composition ECM and in the 
integrin profile of human dermal fibroblasts, which is ultimately characterized by the loss of 
collagen I protein as well as the loss of integrin alpha-11 expression.
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2.2 Results and Discussion 
ECM/AM microarray 
A microarray for ECM/AM targets (SA Biosciences) was used to compare the expression 
of ECM/AM cDNA levels between human embryonic stem cells (hESC), and human dermal 
fibroblasts grown with (iRC) or without FGF2 (hDF) (Figure 2.1). A total of 96 target genes were 
analyzed, and 25 of them were determined to be detectable in treatments and controls. Fifteen 
most highly changed genes were chosen for subsequent validation by qRT-PCR (Figure 2.3a). 
When normalized to hESC, iRC showed a trend towards the gene expression profile of hESC, 
which was demonstrated with a 17-fold down-regulation of integrin alpha-11 (α11) and a 5-fold 
up-regulation in matrix metalloproteinase-1 (MMP1) (Figure 2.2). This suggested that iRC might 
be building a less collagen-I rich matrix mediated by MMP1 activity. 
Figure 2.1 Schematic Extracellular Matrix and Adhesion Molecule Array  
A human extracellular matrix and adhesion molecule hybridization array containing 96 target 
genes. 
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Figure 2.2 Effect of FGF2 on expression of extracellular matrix and adhesion 
molecules 
Expression was assayed in fibroblasts grown for 30 days in 5% oxygen without FGF2 
(hDF-5) or with FGF2 supplementation (hDF-5-FGF2) and human embryonic stem cells 
(hESC) by Extracellular Matrix and Adhesion Molecule Array. Data were normalized to ribosomal 
protein Rsp27A using densitometry. 
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qRT-PCR confirmation of array targets 
qRT-PCR was used to validate the results of the ECM/AM array for the 15 most highly 
deregulated targets in hDF, iRC, and hESC. FGF2 supplementation under 5% oxygen resulted 
in a 17-fold down-regulation in Itga11, and a 35-fold up-regulation in interstitial collagenase 
matrix metalloproteinase-1 (Mmp1) (Figure 2.3a), which is responsible for collagen-1 
degradation. Additionally, we observed a 2-fold up-regulation in Itgb1 and a 4-fold down-
regulation in Fibronectin 1 (Fn1) (Figure 2.3a). Collectively, this data suggests that in human 
dermal fibroblasts, treatment with FGF2, under low oxygen conditions induces a shift away from 
a collagen I based attachment. Deregulation of expression for the majority of the ECM and 
adhesion molecules profiled by qRT-PCR was induced by lowering the oxygen concentration to 
5%, and this effect was further potentiated by the addition of FGF2 (Figure 2.3a).  
The observation that iRC attachment protein expressions were not significantly down-
regulated prompted us to analyze expression of other a/b integrins in order to determine if other 
integrin pairs were substituting for Itga11 activity. Comparison of hDF cultures with iRC showed 
an increase in the transcript level for several integrin subunits (α3, α5, α6, β1, β3, β5) (Figure 
2.4) with up-regulation of α6 and β3 with the being most highly up-regulated by 10- and 4-fold 
respectively.  
Out of the up-regulated integrin subunits identified, the potential integrin pairs were 
identified as follows: α6β1 and α6β4 are receptors for laminins, which are predominately 
present in basement membrane [46], and αVβ3 and α5β1 are RGD integrin receptors, and are 
receptors for fibronectin [47]  and vitronectin [48] respectively. In summary, when comparing 
potential pairs for all up-regulated α and β subunits, substrates being bound are likely laminins, 
and RGD receptor-binding pairs, fibronectin, vitronectin. 
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Figure 2.3. Effect of FGF2 on RNA expression levels of extracellular matrix and adhesion 
molecules.   
(a) Expression was assayed in fibroblasts grown for 30 days in 5% oxygen without FGF2 
(hDF-5) or with FGF2 supplementation (hDF-5-FGF2) by qRT-PCR. Data were normalized to 
actin in control fibroblasts grown in atmospheric oxygen without FGF2. Expression levels are 
presented as fold change in expression using delta-delta CT method. (b) Western blotting for 
select ECM and AM proteins. Data were normalized to actin in fibroblasts grown in atmospheric 
oxygen without FGF2 (hDF). FN1 – fibronectin; COLI - collagen I, COLIV – collagen IV, ITGA11 - 
integrin α11, ITGB1 – integrin β1. Error bars indicate SD (n=3) 
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Figure 2.4. Expression of integrin alpha and beta subunit RNAs by qRT-PCR 
Levels of integrin alpha and beta subunit RNAs were assayed in fibroblasts grown for 30 days 
in 5% oxygen without FGF2 (hDF) or with FGF2 supplementation (hDF-5-FGF2) by qRT-PCR. 
Data were normalized to actin in control fibroblasts grown in atmospheric oxygen without FGF2. 
Expression levels are presented as fold change in expression using delta-delta CT method. 
Error bars indicate SD (n=3). 
Western blot: ECM/AM targets 
Signal transduction pathways triggered by differential binding of ECM have effects on 
cell behavior, such as proliferation, survival/apoptosis, shape, polarity, motility, gene expression 
and differentiation [49]. To determine if the transcriptional changes induced by FGF2 and low 
oxygen resulted in changes in protein levels, we characterized levels of protein expression by 
Western blotting (Figure 2.3b). Correlating gene expression levels with protein expression 
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indicated that for a few of the targets, more specifically FN1 and ITGA11, the regulation 
happens at the transcriptional level (Figure 2.4b).  
When grown in the presence of FGF2, fibroblasts decreased production of COL1 and 
increased production of ITGB1 significantly, while levels of COL4 remained unchanged (Figure 
2.3b). However, protein expression levels for COL1, COL4, and ITGB1 levels did not correlate 
with transcript levels (Figure 2.3b).  
Considering the major effects that addition of FGF2 had on altering gene and protein 
expression levels, we decided to make FGF2 the main variable for our studies. To further 
Figure 2.5. Immunocytochemistry of ECM deposited by hDF and iRC 
Immunocytochemistry of fibroblasts labeled with primary antibodies against collagen-I, laminin- 
111 and vitronectin and detected with secondary antibodies conjugated to AlexaFluor568 (red). 
Images taken at 10x magnification, scale bar indicates 100µM.  
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investigate the role of FGF2 on modifying the niche of primary human dermal fibroblasts, we 
assayed expression of several other proteins hypothesized to be involved in regulating the 
cellular niche, and saw a decrease in protein levels of ITGA11, COLI, and an increase in FN1, 
FAK, TGF-β1 and TGF-β2. Levels of COLIV remained consistent across all treatments (Figure 
2.3b).  
While the observed decrease in collagen-I protein expression does not correlate to a 
decrease in message level, the increase in MMP1 expression suggested that COLI maybe 
regulated by MMP1 proteolytic degradation.  Western blot analysis for α11, and COLI confirmed 
that they were both down-regulated in cells treated with FGF2 under low oxygen conditions 
only, and no change was observed when no FGF2 was present (Figure 2.3b). This observation 
confirmed that the change in α11, and COL-I expression was an FGF2-mediated effect. 
Additionally, we looked at the overall localization of COL-I, Versican and Laminin-111 in hDF 
and iRC cells. In iRC cells, Col-I appeared to have a change in organization, while Versican and 
Laminin-111 seemed to be more highly expressed when in low oxygen with FGF2 (iRC)  (Figure 
2.5). This further indicates that low oxygen and exogenous FGF2 experimental culture 
conditions are creating a functional shift in the ECM/AM of hDF.  
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2.3 Conclusions 
Here we show that with the addition of exogenous FGF2, hDF alter the transcription and 
translation of extracellular matrix proteins, adhesion molecules and matrix remodeling enzymes.  
Attachment to ECM is of importance in many biological situations, of which, human 
embryonic stem cells are a model for maintenance of pluripotency in vitro. hESC colonies are 
comprised of highly adherent pluripotent progenitors. Dissociation of cell-cell attachments leads 
to an increased rate of differentiation, and cell death [50]. This suggests that the extracellular 
niche, as well as cell-cell junctions play a major role in the assembly and subsequent 
maintenance of pluripotent human embryonic stem cell colonies. In addition to attachment, 
human embryonic stem cells are dependent on the addition of basic fibroblast growth factor 2 
(FGF2), from either exogenous supplementation, or mouse embryonic fibroblast conditioned 
culture medium [51].  
Just as attachment of hESC is known to play a role in the maintenance of pluripotency, a 
specialized niche is important for phenotype maintenance of adult stem cells [37]. Adult stem 
cells are responsible for the growth, maintenance and overall homeostasis of most adult tissue 
types within the body [52-55]. The survival and maintenance of multipotency is regulated by the 
microenvironment in which they reside [56-59]. Each adult stem cell has its own, dynamic and 
independently complex niche [60, 61]. The niche can be defined as a subset of tissue, cells, and 
extracellular substrates that provide support, and can indefinitely house stem cells. In addition to 
being a place of local homing, this niche provides the cues that provide the ability for the stem 
cell to remain undifferentiated indefinitely [62].  
When analyzing the overall changes in the expression of ECM proteins based on the 
ECM/AM array profile, we saw a down regulation in Col12A1, Col4A2, and Col8A1 in iRC’s. 
Conversely, we saw an up-regulation in Col6a1 and Col6A3. qRT-PCR analysis comparing 
gene expression level between hDF and iRC, showed an increase in the transcript level for 
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several integrin subunits when FGF2 was present in the culture medium. More specifically 
integrin α6 and β3 were the most highly up-regulated by 10- and 4-fold, respectively. Down-
regulation in integrin receptor transcript levels as well as changes in the expression levels of 
matrix remodeling proteins such as MMP’s (up-regulated) argue that iRC cells are undergoing a 
remodeling of extracellular matrix attachment. We observed an up-regulation in Sparc which 
has been implicated in both development and injury response with biological implications in cell 
shape, growth factor efficacy, and ability to affect the expression of MMPs [46]. From the 
transcriptional changes observed we hypothesize that iRC cells are shifting their attachment 
away from collagen-I and likely to laminins. 
The novel fibroblast phenotype observed here can have several important biological 
implications especially considering that fibroblasts represent the most abundant cell type among 
the various cell types that participate in the wound healing process [63]. After injury, fibroblasts 
replace the wound with granulation tissue, composed of fibronectin and collagen-I [64]. As the 
wound is re-vascularized, fibroblasts acquire an activated, highly contractile phenotype to close 
the wound with deposition of collagen-I dense scar tissue [63]. Subsequent to wound closure, 
remodeling events occur, which induce a change of collagen-I dense scar tissue into more 
functional tissue architecture. In extreme cases when routine healing process is compromised 
due to severe trauma, or upon deregulation normal fibrotic/healing response; irreversible fibrosis 
occurs, resulting in deposition of excessive fibrous connective tissue and dense scar formation. 
Currently, choric fibrosis is irreversible [65].  
The fibroblast phenotype described here, which no longer synthesizes nor anchors to 
collagen-I, is in line with a fibroblast phenotype that is able to participate in wound healing with a 
less fibrotic response. Previous work from our lab using the same culture conditions has 
demonstrated reduced collagen deposition in an in vivo mouse skeletal muscle regeneration 
model [26]. That data serves as a characterization to support the improved functional outcome, 
which when combined with the molecular characterization described in this part of the thesis 
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allows us to hypothesize that iRC are becoming less likely to participate in scar formation, and 
the iRC fibroblast may be able to participate in wound healing with a less fibrotic response. 
Furthering our understanding of the molecular mechanisms which are controlling the ECM / AM 
shift we see when fibroblasts are transitioning from hDF to iRC may provide useful insight into 
potential therapeutic targets for fibrotic conditions such as scaring.  
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Chapter 3 
Analysis of an Erk1/2 Mediated Down-Regulation of Integrin 
Alpha-11 in Induced Regeneration Competent Cells 
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3.0 Abstract 
Deposition of collagen-based extracellular matrix by fibroblasts during wound healing 
leads to scar formation - a typical outcome of the healing process in soft tissue wounds. The 
process can, however, be skewed in favor of tissue regeneration by manipulation of the wound 
environment. Under low oxygen and FGF2 supplementation, fibroblasts dramatically alter 
expression of many genes among which the most significantly deregulated are extracellular 
matrix and adhesion molecules. Therefore we hypothesize that low oxygen conditions and 
supplementation with FGF2 can provide extracellular cues that drive wound fibroblasts 
towards a pro-regenerative phenotype. Here we investigate the mechanism of a collagen I 
binding integrin α11 (ITGA11) decrease in response to low oxygen-mediated FGF2 effects in 
dermal fibroblasts. Using RT-PCR, qRT-PCR, Western blotting and immunocytochemistry, we 
describe significant down-regulation of ITGA11. We show that loss of ITGA11 requires FGF2-
induced ERK1/2 activity, and in the presence of FGF2, ITGA11 expression cannot be rescued 
by TGFβ1, a potent activator of ITGA11. Our results indicate that FGF2 may be redirecting 
fibroblasts towards an anti-fibrotic phenotype by overriding TGFβ1-mediated ITGA11 
expression.  
Objectives and Hypothesis 
The objective of this work is to investigate the mechanism of the low oxygen mediated-
FGF2 effect on integrin alpha-11, with the hypothesis that FGF2 signaling is suppressing 
transcriptional activity of integrin alpha-11 either directly, or indirectly.  
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3.1 Introduction 
Regulation of cell fate through modulation of ECM leading to altered mechano-biological 
cues suggests that extracellular matrix and binding with integrin is involved in cellular phenotype 
[1]. Recent discoveries in stem cell biology describe how the modulation of extracellular matrix 
and the changes in mechano-biological cues from the structural properties of extracellular 
matrix composition affect stem cell fate.  While stem cell fate (differentiation or maintenance of 
multipotent and pluripotent cell phenotypes) in vitro can be controlled by genetic and molecular 
mechanisms, involving the presence of growth factors for pluripotency support, and transcription 
factors for the induction of pluripotency [2], new evidence suggests that interactions between 
extracellular matrix proteins and integrin receptors play a role in controlling stem cell fate [1]. A 
functional role for integrin expression in cell niche has not been directly identified [3].  
Integrins are a large family of heterodimeric, transmembrane cell surface molecules 
which serve as the main receptors for extracellular matrix (ECM) [4]. They provide for cell 
attachment, motility, and sensing of the extracellular environment. The different integrin 
heterodimers have been characterized for their specificity for different ECM proteins [5], and 
some integrins are known to have their affinity for ligand modulated by intracellular events, so 
called ‘inside out’ signaling. Responses to the ECM mediated by integrins, so called ‘outside in’ 
signaling, such as attachment dependent response to growth factors or avoidance of apoptosis 
[6], have also been demonstrated in a variety of model systems. Functional integrin receptors 
consist of an alpha and a beta subunit [7, 8], and five integrin heterodimers have been 
described as collagen receptors; α1β1, α2β1, α3β1, α10β1 and α11β1 [9-12]. Expression of all 
these receptors except α10β1 has been described in dermal fibroblasts, where they contribute 
to collagen type I binding [13] and collagen production [14]. 
Integrins localize in cell adhesion sites that are composed of a complex assembly of 
additional proteins and form a diverse and elaborate network [15]. The network in which 
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integrins have structural and molecular regulatory roles is known as the integrin adhesome [15], 
and consists of over 232 components. The majority of them (148 components) localize directly 
at the site of adhesion, while the remaining 84 components can associate with the adhesion 
transiently, and participate in subsequent signaling [16]. The integrin adhesome is a large, 
dynamic, and complex system that is not well characterized and still poorly understood.  
At the tissue level, growth factors represent the main regulators of integrin expression. 
TGFβ controls the transcription of numerous integrins in several cell types and tissues, and in 
most cases stimulates integrin expression. Induction of integrin expression by TGFβ can be 
driven by cooperative signaling between the integrin and TGFβ, thereby creating a forward loop 
[17]. TGFβ not only regulates the expression of integrin ligands—including several members of 
the collagen family—but also stimulates the expression of integrin-associated proteins—
including disabled 2, ILK, kindlin 1, paxillin and PINCH—which can also increase integrin 
activation [18]. Therefore, the transcriptional control exerted by TGFβ can strongly affect 
integrin-mediated processes. Understanding the molecular mechanisms by which integrins 
mediate structural, biochemical and mechanical cues are involved in and subsequent 
determination of cell-fate is necessary.  
Integrin α11 is a major fibrillar collagen receptor in fibroblasts [19, 20], pairs with integrin 
β1, binds with high affinity to collagen I [21], and is involved in myofibroblast differentiation and 
collagen reorganization [22]. α11 expression has been described in vitro in human dermal 
fibroblasts [23] fibrosarcoma HT1080 [24], glioblastoma [25], and mouse embryonic fibroblasts 
[20, 26]. Transcription of integrin α11 gene ITGA11 is regulated by TGFβ1 via SMAD2/3, EST1, 
and SP1 transcription factors binding within the ITGA11 proximal promoter [27] or by TGFβ2 via 
SMAD2/3 binding to a sequence in the ITGA11 distal promoter [28]. 
FGF2 supplementation under low oxygen in vitro significantly alters fibroblast 
participation in wound healing, leading to a more pro-regenerative healing after cell 
transplantation in vivo [29]. Human dermal fibroblasts cultured under these conditions 
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significantly alter the expression of many genes, including activation of select stem cell genes 
[30].  
In humans, five FGF2 isoforms can occur (18, 22, 22.5, 24 and 34 kDa), which display 
different subcellular localizations and contribute to different cellular behaviors [31, 32]. The 18 
kDa FGF2 is known as the low molecular weight isoform, and signals predominately through the 
mitogen-activated protein kinase (MAPK) pathway [33]. Additionally, 18kDa FGF2 can also 
activate PI3K and PLCγ pathways. Combined, these pathways control cell type-specific 
signaling, and downstream effects include proliferation, growth, differentiation, migration, and 
survival [31, 34]. Additionally, the other isoforms of FGF2 are considered high molecular weight 
(HMW) and have intracellular effects on cells [32, 35]. NIH-3T3 cells, which were over-
expressing LMW FGF2 (FGF2), were shown to modulate integrin expression, they increased 
α5β1, and conversely, NIH-3T3 cells over-expressing HMW isoforms, down-regulated α5β1. 
The observed increase in α5β1 was shown to occur through increased rates of transcription, 
however both β1 transcript was not increased, both α5β1 protein increased [36, 37]. FGF2 has 
been observed to down-regulate α11 in mesenchymal stem cells as well as mouse embryonic 
fibroblasts, but the mechanism has not been described [22, 38].  
When analyzing the changes in ECM and AM between hDF and iRC (Chapter 2), FGF2 
was required for the shift. Additionally, FGF2 has been observed to down-regulate α11 in 
mesenchymal stem cells as well as mouse embryonic fibroblasts, but the mechanism has not 
been described [22, 38]. 
We have found that α11 is the most altered integrin in human dermal fibroblasts grown in 
low oxygen with FGF2 supplementation [39]. Here we describe the mechanism in the oxygen-
mediated FGF2 effect on regulation of α11 expression in human dermal fibroblasts.  
Decrease in expression of collagen-I binding integrins, in concert with decreased 
collagen-I expression and increased expression of collagen-I cleaving matrix metalloproteinase 
(MMP1) serve as an indication that FGF2-treated human dermal fibroblasts under low oxygen 
 73 
conditions may be transitioning away from the production of a collagen-I rich niche. 
Understanding the molecular mechanisms by which integrin-mediated cellular phenotype is 
defined is necessary for many biological implications. Here we investigate the molecular 
mechanism of oxygen-mediated FGF2 effect on regulation of α11. 
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3.3 Results and Discussion 
Down regulation of Itga11: mRNA, protein, and localization 
The observed loss of α11 from iRC cells by RT-PCR (Figure 3.1a) and by Western blot 
(Figure 3.2b) led us to further characterize the loss of α11. To determine a timeline for the 
down-regulation of Itga11 transcript, samples were collected for qRT-PCR analysis every 24 
hours for seven days after addition of FGF2. Down-regulation of α11 was first observed 48 
hours after the addition of FGF2, and transcript levels continued to decrease through day 7 
(Figure 3.1c).  
Next we asked if α11 was being lost from focal adhesions where it is normally localized 
in hDF. Immunocytochemistry was used to determine if α11 was being lost from focal adhesions 
in hDF compared to iRC. When compared, hDF showed the presence of α11 in focal adhesions, 
while cells treated with exogenous FGF2 showed loss of α11 protein from focal adhesions 
(Figure 3.1d).  
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Figure 3.1 Expression localization and down regulation of integrin alpha-11 
(A) RT-PCR for ITGA11, ITGB1 (positive control) and Actin on human dermal fibroblasts at 5% 
oxygen, with and without FGF2 (hDF and iRC respectively). (B) Western blots were probed with 
primary antibodies against Itgα11 and actin. Protein was detected with HRP- conjugated 
secondary antibodies. hDF at 19% oxygen for 7 days were used as a positive control, and 
human embryonic stem cells as a negative control. iRC show a down-regulation of itgα11 total 
protein when compared to control cells. Error bars indicate SD (n=2).  
Comparison of Itga11 transcript half-life and FGF2 treatment 
In order to discern the mechanism by which FGF2 addition decreases α11 expression 
several assays were used to understand the changes in expression at the transcriptional as well 
as translational level. 
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In an attempt to elucidate if FGF2 has a direct effect on the transcription of Itga11, we 
incubated hDF in FGF2 for 24, 48 and 72 hours as a control (Figure 3.2a), alpha-amanatin for 4, 
8 and 24 hours (Figure 3.2b) and then measured the levels of transcript (Figure 3.2b, left half). 
In parallel we incubated hDF in FGF2 for the same amount of time in parallel. α-amanatin is an 
inhibitor of RNA polymerase II, and therefore should inhibit all new transcription. When 
comparing hDF in FGF2 and hDF with blocked transcription by 8 hours in α-amanatin, less 
Itga11 transcript is present when compared to the same time point in FGF2 treatment, however 
after 24 hours the levels look comparable (Figure 3.2b). From this we conclude that addition of 
FGF2 to treated cells is capable of inhibiting new transcription of Itga11 but not likely as a direct 
effect, as a direct effect would show similar rates to blocked transcription. Thus likely it is a 
downstream effect of FGF2 activation that inhibits new transcription of Itga11.  
Figure 3.2 Comparison of effect of alpha-amanatin and FGF2 on levels of Itga11 
transcript 
(a) Human dermal fibroblasts incubated in FGF2 for hours indicated, RT-PCR for ITGA11 
transcript, actin used as loading control (b) RT-PCR for ITGA11 when cells were incubated in 
parallel in a-amanatin and FGF2 at time points indicated. Actin used as a loading control. 
Methylation status of CpG islands 
The methylation status of CpG islands within proximal promoter regions is known 
to regulate gene expression. Total genomic DNAs from hDF and iRC were digested with 
methylation-sensitive and methylation-dependent restriction enzymes and subjected to PCR 
with tiling primers that spanned two CpG islands within the ITGA11 gene (Figure 3.3a). 
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Genomic PCR with tiling primers spanning both CpG islands resulted in no PCR amplification for 
any of five regions when the DNA was digested with a methylation-sensitive restriction enzyme 
(HhaI whose cutting at CpG is blocked by methylation), and amplification of all five amplicons 
when the DNA was digested with a methylation-dependent enzyme (McrBc which cuts at 
methylated cytosines). This suggested that there was no apparent change in the methylation 
status of CpG islands when comparing cells expressing ITGA11 and cells not expressing 
ITGA11 (Figure 3.3b). Thus, the ITGA11 promoter is not methylated at the sites analyzed and 
the methylation status of the ITGA11 promoter showed no apparent change in its methylation 
status for the regions we amplified, and the FGF2-mediated down-regulation of α11 likely is not 
due to promoter silencing through methylation. 
Figure 3.3 Effect of FGF2 on methylation of CpG islands in the ITGA11 promoter 
(a) Genomic locations of CpG islands within ITGA11 promoter were identified using 
Transcriptional Regulatory Element Database and CpG islands were mapped using MethPrimer 
software. (b) PCR was performed with primers tiling two CpG islands mapped to primer 
sequences within the promoter region using NCBI Primer Blast.  Control genomic DNA was 
used in addition to DNA from experimental treatments. DNA was subjected to digestion with a 
methylation-sensitive restriction enzyme (HhaI), methylation-dependent restriction enzyme 
(McrBc), or a sham digest was performed.  
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hsa-miR-29 levels after addition of FGF2 
In a panel of TGFβ-1-responsive fibrosis-associated genes α11 was shown to be 
repressed by miR-29 through knock-down studies [40]. miR29 was shown to suppress TGF-β1 
up-regulated fibrosis-associated genes and, in knockdown, expression of fibrosis-related targets 
appear to have been repressed by miR-29. This suggests that miR-29a up-regulation 
suppresses the expression of α11 [40]. Additionally, miR-29 is the only miR with sequence 
homology to Itga11, therefore making it a candidate for α11 post-transcriptional regulation. To 
determine if the miR-29 family was regulating the expression of α11 in hDF and iRC we 
investigated the level of total miR-29a and miR-29b in iRC's in comparison with hDF. Levels of 
miR-29 were assayed by qRT-PCR and no change was observed between hDF and iRC. qRT-
PCR was used to analyze the expression levels of miR-29a and miR-29b in both hDF and iRC.  
Expression levels of miR29a remained consistent in hDF and iRC. Consistent levels of miR-29 
in conjunction with loss of α11 transcript suggested a non-miR-29-mediated gene silencing. 
(Figure 3.4). 
Figure 3.4 Effect of FGF2 on expression of hsa-miR-29a.  
qRT-PCR reactions were performed using primers for hsa-miR-29a-3p and hsa-miR-29a-5p. 
Expression of hsa-miR-RNU6 was used for normalization. Expression levels were calculated 
using the delta delta-Ct method. hDF – fibroblasts grown at 5% oxygen, iRC - fibroblasts grown 
at 5% oxygen with FGF2.  
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TGF- β1 regulation of α11 
TGF-β1 is a potent, dynamic regulator of ECM and AM expression, and α11 up-
regulation has been shown to be dependent of TGF-β-mediated signaling [22, 28, 41]. TGF-β1 
induces expression of α11 in primary fibroblasts through SMAD 2/3 and Sp1-mediated 
activation of the ITGA11 promoter (Figure 3.5) [41]. To determine if an increase in TGFβ-1 
resulted in the down-regulation of α11 in our cells, we assayed the endogenous levels of TGFβ-
1 in iRC cells when compared to hDF. The data (Figure 3.6a) showed that the increase in 
TGFβ-1 levels in iRC cells did not translate to an increase in α11 protein expression (Figure 
3.6a). To assess if the presence of TGFβ-1 affected the expression of α11 in our cells, we 
treated hDF and iRC with exogenous TGFβ-1. A large range in TGFβ-1 concentrations was 
chosen to assess dose-dependence over a broad range of physiological concentrations. hDF 
were treated with increasing concentrations of TGFβ-1 in the absence of FGF2. Both low 
(0.05ng/mL-1.0ng/mL) and high (5ng/mL-50ng/mL) concentrations of TGFβ-1 induced an 
increase in α11 (Figure 3.6b). 
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Figure 3.5 The transforming growth factor beta signaling pathway 
Activation of latent TGFβ1 allows binding to TβRI, this binding results in the recruitment of TβRII 
which phosphorylates Smad2 and Smad3. Activated Smad2 and Smad3 heterodimerize with 
Smad4 and translocate to the nucleus. Smad2/3/4 complex act with cofactors and other 
transcription factors to induce or repress gene expression.  Smad2/3/4 complex is known to 
induce expression of integrin alpha-11.  
Due to the observation of an increase in TGF- β1 in iRC, and a loss of α11, we asked 
whether the FGF2 mediated loss in α11 occurs upstream of TGF-β1-mediated α11 expression. 
hDF and iRC were treated with three different concentrations of TGFβ-1 (0.1, 1.0, 10.0 ng/mL) 
in culture medium and assayed for α11 expression at day 7. Addition of different concentrations 
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of TGFβ-1 in hDF and iRC resulted in a TGFβ-1 dose-dependent down-regulation of α11 
expression and the presence of FGF2 strongly affected the signal (Figure 3.6c, right side). 
Cultures supplemented with TGFβ-1 and treated with FGF2 showed a down-regulation of α11 
protein expression by Western blot (Figure 3.6c, right side) and was quantified using ImageJ 
(Figure 3.6d). These findings demonstrate that α11 down-regulation as a result of exogenous 
FGF2 addition occurs upstream of TGFβ-1 mediated regulation.  
Additionally, to determine if other fibrotic associated molecules were involved with this 
transition, we looked at alpha-smooth muscle actin as another TGFβ-1 mediated response 
factor and found that it responded similarly with FGF2 over-riding the TGFβ-1-induced increase 
in alpha-smooth muscle actin (Figure 3.6e). 
Figure 3.6 Effect of transforming growth factor TGFβ1 on expression of ITGA11. 
(a) Total amounts of endogenous TGFβ1 and TGFβ2 in cells grown under different conditions. 
(b) Levels of ITGA11 in fibroblasts grown in low and high concentrations of exogenous TGFβ1 
and (c) levels of ITGA11 in fibroblasts grown in low and high concentrations of exogenous 
TGFβ1 in the presence or absence of FGF2. (d) Quantification of ITGA11 expression by 
densitometry. (e) Expression of alpha smooth muscle actin (αSMA) in cells grown with TGFβ1 in 
the presence or absence of FGF2. Western blotting, actin was used as a loading control. 
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FGF2  mediated ERK1/2 regulation of α11 expression 
The MAPK pathway involving ERK1/2 activation is a very robust pathway involved 
in many cellular processes and is also the canonical pathway for FGF2 signaling (Figure 
3.7) [42]. Addition of exogenous FGF2 to the culture media resulted in phosphorylation of 
ERK1/2 kinase within 30 minutes of treatment (Figure 3.8a).  
Figure 3.7 Basic fibroblast growth factor activation pathway 
Binding of FGF2 to FGFR activates FRS2 through phosphorylation on several residues that 
facilitate the recruitment of the SOS and GRB2 adaptor proteins that trigger downstream 
activation of several kinase pathways effecting transcription. 
To determine if ERK1/2 was involved in down-regulation of α11 expression upon addition of 
FGF2 we assayed ERK1/2 activation to determine its potential role in this process.  FGF2 was 
added to human dermal fibroblasts that were grown under low oxygen conditions and treated 
with an ERK1/2 inhibitor (U0126) at a concentration that blocked ERK1/2 activation (Figure 
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3.8b).  A concentration of 80µg/mL U0126 completely inhibited ERK1/2 activation. Western blot 
analysis showed that iRC in the presence of  80µg/mL ERK1/2 inhibitor, maintained expression 
of α11 at levels consistent with hDF that are grown in the absence of exogenous FGF2 (Figure 
3.6b). 
Figure 3.8 Effects FGF2-mediated ERK activation on expression of ITGA11. 
(a) Levels of ERK (ERK1/2) and phosphorylated ERK (pERK1/2) kinase. (b) Levels of ERK1/2 
and phospho-ERK1/2 kinase in the presence of increasing concentrations of ERK1/2 inhibitor 
U0126. Before assaying for ERK phosphorylation, cells were cultured without serum for 30 
minutes. (c) Levels of ITGA11 in cells treated with 80µg/ml ERK inhibitor and FGF2. Western 
blotting, actin was used as a loading control. 
Moreover, Western blot analysis of hDF treated with ERK1/2 inhibitor U0126 (with or without 
FGF2) showed increased α11 expression. These results support the hypothesis that ERK1/2 
signaling is involved in the regulation of α11 expression.  Notably, when ERK1/2 phosphorylation 
was blocked by U0126, iRC maintained higher α11 expression levels, indicating that activation of 
ERK1/2 was required for the down-regulation of α11 protein expression (Figure 3.8c). 
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3.4 Conclusions 
Presentation of fibrosis in many organs is similar, regardless of initiation, and is 
mediated by the activation of fibroblasts into an activated fibroblastic phenotype. Therapy to 
reverse, halt or improve an existing fibrotic event is not available and still in clinical development 
[43]. Activated fibroblasts are thought to be largely responsible for the deposition of extracellular 
matrix [44].  We hypothesize that changing cellular signaling in the injury environment can 
modulate aberrant healing mechanisms, and scar formation from a typical fibrotic response 
should not remain the unfortunate outcome of the soft tissue wound healing. Regulation of cell 
fate through modulation of ECM suggests that extracellular matrix and integrin binding is 
involved in determining the cellular phenotype [1] yet, a functional role linking integrin 
expression profile with the cell fate has not been directly identified [3]. 
TGF-β1 controls the transcription of several integrins throughout many different tissues 
and cell types. Additionally, in some cases the down-regulation of integrins has been reported 
via TGF-β1 mediated signaling, however this is less often the case.  TGF-β1 mediated integrin 
expression in many cases can be driven by corporative signaling, such that integrin activation 
regulates it’s expression, as well as TGF-β1 [17]. TGF-β1 is a very well known regulator of 
many ECM molecules and integrin-associated proteins. Integrins are described as activators of 
TGF-β1 as well as receptors for TGF-β1 [45]. Taking all of this in sum, the relationship between 
TGF-β1 and integrin mediated signaling is complex, however these pathways are involved in 
pathologies with fibrotic pathologies in cancer, wound-healing, and chronic fibrotic conditions 
[18]. 
Cutaneous wound healing in mammals proceeds through a sequence of several phases, 
including rapid production of TGF-β [46], immediate inflammatory response, cell proliferation 
and migration, and contraction and remodeling of ECM. Among various cell types that 
participate in the process, fibroblasts represent the most abundant cell type. Fibroblasts replace 
85 
the wound with granulation tissue composed of fibronectin and collagen-I. As the wound is re-
vascularized, fibroblasts acquire an activated, highly contractile phenotype to close the wound 
with deposition of collagen-I dense scar [47]. In extreme cases when the routine healing 
process is compromised due to severe trauma, or deregulation of normal fibrotic/healing 
response irreversible fibrosis occurs resulting in deposition of excessive fibrous connective 
tissue and dense scar formation. Pathological fibrosis is regulated by ECM secreting activated-
fibroblasts and accompanies the progression of many chronic inflammatory diseases. Normal 
scar reorganization involves the remolding of initially deposited collagen-I followed by full or 
partial restoration of prior tissue function, however fibrotic pathologies compromise the function 
of affected organs and tissues. Irreversible fibrosis is responsible for death from end-stage liver, 
kidney, heart diseases, idiopathic pulmonary fibrosis [44] and unresolved fibrotic conditions are 
features of many autoimmune diseases [48]. TGF-β1 mediates the fibrotic response through 
activation of ECM genes [49], and suppression of ECM regulators by degradation [50]. In fibrotic 
conditions, TGF-β1 induced Smad3 signaling results in deposition of large amounts of collagen-I 
by activated-fibroblasts [51, 52].  
FGF-2 has a robust myogenic effect on fibroblasts, and its participation has been linked 
to multiple fibrotic disorders in oral submucosa [53], pulmonary fibrosis [54, 55] and renal 
fibrosis [56] to name a few. These studies allow us to draw the conclusion that FGF2 can be 
induced by TGF-β, which creates a complex relationship between these signaling molecules [56, 
57].  
To add to this broad range of effects, FGF-2 has also been shown to inhibit TGF-β 
induced myofibroblast differentiation [58-62] and in cases of non-pathological wound healing, it 
has been shown to be able to induce apoptosis in myofibroblasts, but not in resident fibroblasts 
which have not taken on a myofibroblast phenotype [62, 63]. These studies indicate that FGF2 
has regulatory roles in mediating the balance between scar and tissue formation in wound 
healing, as it triggers proliferation of fibroblasts, yet keeps myofibroblast populations limited 
through 
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apoptosis.  The role of FGF2 signaling in fibrosis remains unclear and continues to get 
increasingly complex, as the regulatory loop connecting TGF-β1 mediated fibrotic conditions and 
FGF2 has yet to be fully defined. 
FGF2 has been shown to be involved in the promotion of several tumor types through 
activating proliferation pathways, and aiding in survival of cancer cells by inducing 
vascularization [64]. The relationship between FGF2 and cancer is not easy to elucidate, as 
FGF2 has also been shown to have a role in tumor suppression [64].  
Integrin α11 has been described as a contributing factor to fibrotic tumor stroma [65]. In 
many cases fibrotic tumors impermeable cytotoxic chemotherapy because they are high density 
[66]. Integrin-α11 contributes to this dense environment through high levels of binding to 
collagen-I [65]. Mitigation of α11 binding through a pathway that can override TGFβ-1 signaling 
could provide therapeutic targets for dense fibrotic tumor stroma. 
Understanding the molecular mechanisms by which integrin-mediated cellular phenotype 
is defined is necessary, and would have a wide range of biological implications. Fibrosis 
research is focused on elucidating molecular mechanisms that can terminate irreversible fibrosis 
[18]. Any progress in the development of a treatment using a common tissue fibrosis pathway, 
especially one that can reduce TGFβ-1 fibrotic conditions, could result in the identification of 
potential therapeutic targets for common cellular pathways. 
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Chapter 4 
Mesenchymal-to-Epithelial Transition in Induced 
Regeneration Competent Cells—Investigating a role for 
Integrin Alpha-11 
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4.0 Abstract 
Advancements in cellular therapy for regenerative medicine currently are limited by 
clinically non-compliant cell sources. To this end, the importance of  understanding the 
molecular mechanisms underlying the cell-fate conversion and cell-fate reversal for 
development of autologous cell sources is becoming increasingly clear. Here we describe 
changes in the human dermal fibroblasts (hDF) undergoing induced regeneration competence 
(iRC), a process that is defined by lowered oxygen with exogenous FGF2 supplementation, and 
characterized by the induction of stem cell gene expression and increased cellular life span in 
vitro. In this chapter we characterize the presence of focal adhesions and focal adhesion kinase 
activity, and lay the groundwork to support the hypothesis that that mesenchymal-to-
epithelial transition (MET) may be mediating a shift in the extracellular matrix and 
adhesion molecule profile. We identify early MET transcriptional targets, confirm that our 
treated cells are in the initiation stages of MET, and try to get a complete transition 
accomplished via a 3D cell culture protocol. While complete MET is not achieved using our 
culture conditions alone, the partial transition we observe may lead to improved trans-
differentiation protocols, and ultimately result in the development of clinically compliant cells 
sources.  
Objectives and Hypothesis 
This part of my work aims to determine if the transition from a fibroblast to an induced 
regeneration competent cell, induced by our culture conditions, proceeds through MET, and to 
demonstrate if this transition is a consequence of down-regulation of α11 expression. 
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4.1 Introduction 
Study of cell-fate conversion through the induction of pluripotency is a critical model 
system, however progress towards defining methods for generation of an autologous, FDA 
compliant cell source for clinical applications is still necessary. We have developed a novel 
approach that is characterized by the induction of stem cell gene expression and increased 
cellular life span in human dermal fibroblasts in vitro. Our system does not utilize the use of 
transgenes, and is characterized by use of defined culture conditions involving culturing cells at 
5% O2 and supplementation with FGF2 [1]. Understanding the molecular mechanisms 
underlying the cell-fate conversion observed in hDF grown in 5% O2 with FGF2 (iRC) and cell-
fate reversal is important for the development of autologous cell sources as therapeutics, while 
maintaining a clinically compliant derivation protocol. Cells undergoing a MET transition show 
some features similar to iRC cells. For this reason we decided to study the molecular 
mechanisms of MET in order to determine if MET is the mechanism by which our defined 
culture conditions activate stem cell gene expression in hDF.  
Induced pluripotent stem cell (iPSC) derivation methods gave what were once thought 
terminally differentiated cells [2, 3] the potential to be autologous cell sources for a wide variety 
of applications, however to date there have been no examples to demonstrate that 
reprogrammed cells are clinically compliant. Initial iPSC screens looked at changes in 
epigenetic state, as well as transcriptional changes throughout the reprogramming process and 
one of the discoveries showed that mesenchymal-to-epithelial transition was a requirement for 
reprogramming of somatic cells to a pluripotent state [4, 5]. EMT and its reverse, MET are 
characterized by changes in the extracellular matrix (ECM) and subsequently the adhesion 
molecule (AM) expression profile. During EMT, epithelial cells must break down the basement 
membrane components, and modify attachment substrates in order to attach to a distinct niche 
[6]. This has been demonstrated by studies focused on Rho-mediated basement membrane 
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breakdown which initiates early-stage developmental EMT [7]. Moreover, altered expression of 
metalloproteases [8], cytoskeletal proteins [9], collagens [10] and integrins [11] have all been 
linked to EMT and MET.  
ECM is an assembly of fibrous proteins, (i.e. collagen, elastin, fibronectin, laminin) and 
proteoglycans, (i.e. heparan sulfate, chondroitin sulfate), and each tissue has a specific ECM 
composition [12]. ECM was initially thought to serve as a scaffold to maintain tissue and organ 
structure, but is now known to be involved in regulation of cell behavior including cell 
proliferation, growth, survival, morphology, migration, and differentiation [13]. Tissue-specific 
ECM remodeling through degradation and reassembly is constant, and that can be triggered 
and regulated by activation of receptors such as integrins and syndecans [14]. ECM remodeling 
rates are elevated during specialized times, such as EMT and its reverse MET [14].  
One of the first noticeable changes during the reprogramming of fibroblasts is a 
morphological transformation that is characterized by tightly packed clusters of rounded cells, 
resembling MET characteristics [3, 15]. This is not surprising, since throughout the 
development, EMT/MET are frequent and about ten percent of the human genome is 
differentially regulated during these transitions [16]. Moreover, major changes in miRNA profiles 
of cells undergoing EMT/MET have been observed in the transition. When describing EMT, 
down-regulation of E-cadherin and up-regulation of Snail are major regulators and are hallmarks 
of this transition, additionally, the reverse can be said for MET [17]. The relationship between 
these proteins is not complex, however the downstream effects are. Snail is a transcription 
factor that suppresses the transcription of E-cadherin as well as other molecules that are 
responsible for epithelial phenotype [18, 19]. E-cadherin is a transmembrane protein within 
adherence junctions in epithelial cells that maintains cell-cell contact [20].  
When studying either gene expression profiles [21] or morphological changes [17] of 
MEFs during the initial stages of reprogramming to iPSC, there were similarities to MET. This 
pattern included the up-regulation of epithelial genes as well as the down-regulation of key 
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mesenchymal genes. Based on the observed gene expression dynamics three sequential 
phases of reprogramming were identified: initiation, maturation, and stabilization [21]. Changes 
in MET-associated transcript levels were evident when cells were still dependent on 
exogenously supplement reprogramming factors, and occurred before the cells activated an 
embryonic gene expression program of their own [21]. This suggests that MET may be one of 
the earliest changes fibroblasts undergo during cellular reprogramming. Reprogramming of 
mouse fibroblasts to iPSC involves a switch from a mesenchymal to an epithelial transcriptional 
program and changes in cell morphology [17, 21]. Transcription factors used to reprogram 
MEFs were shown to down-regulate mesenchymal genes and activate epithelial associated 
genes. Of these genes, E-cadherin has also been implicated as a regulator and a potent 
controller of human embryonic stem cell pluripotency (hESC). Stabilization of E-cadherin 
through Rho-associated kinase inhibitor (ROCK) has been shown to improve overall viability in 
hESC colony formation during passaging [22-25]. Improving our understanding of the molecular 
steps of reprogramming could lead to improvements and insights into how cellular identity is 
reversed. 
96 
4.2 Results and Discussion 
Focal Adhesion Dynamics 
Vinculin is a focal adhesion protein involved in the regulation and structure of focal 
plaques, and allows visualization of all focal adhesions. To determine if iRC cells, which were 
shown to significantly down-regulate the expression of integrin alpha-11 and collagen-I, were 
remaining adherent, we looked at overall attachment through staining for vinculin. Focal plaques 
were present in iRC and hDF, with iRC appearing to have more focal adhesions by comparison 
of images (Figure 4.1). In order to determine if signaling may be changing through focal 
adhesion kinase (FAK) pathway, RT-PCR for FAK downstream signaling molecules was used 
as an initial screen to identify changes (Figure 4.2a). After no changes were seen in the 
transcript levels of FAK pathway members, FAK phosphorylation status was determined through 
Western blotting of iRC and hDF using hESC as a control (Figure 4.2b).  
Figure 4.1 Vinculin immunocytochemistry 
Immunocytochemistry of fibroblasts labeled with primary antibodies against vinculin and 
detected with secondary antibodies conjugated to AlexaFluor568 (red); and phalloidin 
conjugated to AlexaFluor488 for visualization of actin (green). 
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FAK is a non-receptor protein tyrosine kinase, which is associated with integrin-mediated 
signaling through the FAK-Src complex which regulates mobility, survival and cell spreading 
[26]. Activation of FAK by phosphorylation through integrin clustering leads to auto-
phosphorylation of FAK at tyrosine-397, which serves as a binding site for Src family kinases 
P13K and PLCγ. Src family kinases phosphorylate FAK in the catalytic domain at tyrosine-
576/577, and in the c-terminal region at tyrosine-925 [27]. Activating phosphorylation of FAK at 
tyrosine-397, tyrosine-576/577 and tyrosine-925 were present at comparable levels in hDF and 
iRC (Figure 4.2b). Activating auto-phosphorylation (Y-397) occupied the largest percentage of 
phosphorylation out of total FAK present in both hDF and iRC, with elevated levels of total FAK 
in iRC. Secondary phosphorylation residues (Y-576/577, Y-925) had comparable levels of 
phosphorylation (Figure 4.3b). Elevated levels of total FAK in iRC (Figure 4.2b), presence of 
large numbers of focal plaques (Figure 4.1), and transcriptional changes in other integrin 
Figure 4.2 Focal Adhesion Kinase Signaling 
(a) RT-PCR for focal adhesion kinase associated genes in iRC and hDF cells hESC used as a 
positive control for RT-PCR and actin used as a loading control. (b) Western blot analysis of 
focal adhesion kinase FAK. Actin was used as a loading control. 
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subunits (Chapter 2) suggested that alternate α and/or β subunits and alternate extracellular 
matrix substrates are being expressed substituting for α11β1 collagen-I mediated attachment. 
α6β1 and α6β4 are receptors for laminins predominately present in basement 
membrane [28]. αVβ3, α5β1 are RGD integrin receptors, as well as receptors for fibronectin [29]  
and vitronectin [30]. However, when comparing potential pairs for all up-regulated α and β 
subunits, the substrates being bound are likely laminins, RGD receptors binding pairs, 
fibronectin, and vitronectin. It is important to point out the different receptor binding pairs 
because signal transduction pathways triggered by differential binding of ECM have different 
effects on cell behavior, such as proliferation, survival/apoptosis, shape, polarity, motility, gene 
expression and differentiation. 
Mesenchymal-to-Epithelial Transition 
 Classic EMT is associated with the relocation of cells from a basement membrane 
microenvironment into a fibrillar ECM, and MET can be characterized by the opposite [31]. An 
observed change in expression levels of integrins subunits are often an indication of a change in 
cell to ECM interaction [32]. Additionally, integrin signaling has been described to facilitate the  
Table 4.1 Genes deregulated by mesenchymal-to-epithelial transition 
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transition during EMT, as various integrin expression profiles are specific to both epithelial and 
mesenchymal phenotypes [33].   
Figure 4.3 qRT-PCR for MET genes qRT-PCR for on human dermal fibroblasts, at 5% oxygen 
with and without exogenous FGF2 (hDF and IRC respectively) genes indicated in MET 
transition.  Targets in red are indicative of genes that should be down regulated during MET, 
genes in green are indicative of genes that should be up regulated. 
After observing a change in integrin subunits, and our previous findings that hDF were 
no longer attaching to collagen-I and more likely were making a basement membrane substrate 
(Chapter 2), we wanted to determine if iRC were undergoing a cell-fate conversion towards a 
more epithelial phenotype via MET. We analyzed the gene expression profiles of iRC for genes 
that were associated with the initial stages of MET (Table 4.1). To pick biologically relevant 
targets, we surveyed the Human EMT RT2 Profiler™ PCR Array (SA Biosciences) to identify a 
gene ontology specific to MET and identified significantly up-regulated and down-regulated 
genes from the subset of significantly up or down-regulated genes in the transcriptome array 
100 
[34]. qRT-PCR for selected MET associated genes (Table 4.1) on hDF, iRC were assayed to 
determine if the shift in ECM/AM we were observing was potentially a consequence of MET.  
Human dermal fibroblasts were cultured under the previously described defined 
conditions for 30 days, as this was the time point when stem cell gene expression had been 
previously described, and we expected the most robust phenotype change to take place [1]. 
Analysis by qRT-PCR showed an overall shift in the expression of all assayed MET associated 
genes in iRC  (Figure 4.3). Consistent with expected gene expression changes during MET, we 
observed an up-regulation in Rex1, Dsp, Ecad, Spp1, and a down-regulation in, Ncad, Slug, and 
Snail, suggesting that iRC at day 30 were in the initiation stage of MET.  
Epithelial Cadherin Expression 
To determine if iRC had passed through MET after 30 days of culture, iRC cells were 
analyzed by Western blot for E-cadherin (ECAD) expression, as the shift from N-cadherin 
(NCAD) to ECAD is considered to be a defining characteristic of cells that have completed MET. 
iRC grown for 30 days on tissue culture plastic, did not show expression of ECAD by Western 
blot when compared to hESC positive controls (Figure 4.4a) . 
Previous work on regeneration had shown that a MET transition was fundamental to the 
in vitro generation of neuro-epithelium, and it was necessary for cells to be cultured in 3D in 
order for this transition to occur [35].  To overcome the challenges associated with lack of ECAD 
protein expression under our experimental culture conditions, and based on previous studies 
demonstrating the importance of the 3D environment, we redesigned the experiment using 3D 
aggregation culture of iRC and hDF (Figure 4.4b). However, comparison of ECAD protein 
expression between the 2D cultures with 3D cultures of iRC and hDF did not demonstrate 
differences in protein expression when compared with positive controls (Figure 4.4a). To 
confirm the Western blot results and eliminate the possibility that the Western blot detection limit 
was not producing false negatives, immunohistochemistry was used to analyze ECAD protein 
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expression in our 3D aggregates (Figure 4.4b). However, the immunocytochemistry results 
remained consistent with the Western blot results demonstrating no ECAD expression in our 
aggregates (Figure 4.5b).   
Over-expression of Integrin alpha-11 
Expression of ECAD is a characteristic of late stage MET. As a result of lack of ECAD 
expression, we hypothesized that our iRC cells could be in the initiation phase of MET. Based 
on our previous findings showing α11 to be the most highly deregulated ECM/AM molecule out 
of all targets analyzed (Chapter 2), our next step was to elucidate if there was a potential role for 
the down-regulation of α11 in the acquisition of more epithelial phenotype. An over-expression 
α11 construct containing a c-terminal GFP tag was built. Restriction digestion analysis 
confirmed that clones #6 and #12 contained all inserts in the correct orientation (Figure 4.5). For 
validation of α11-GFP construct (Figure 4.5a) clones #6 and #12 were expressed in ChoK1 and 
Figure 4.3 Induction of Mesenchymal-to-Epithelial transition (MET) via aggregation. 
a)
Total amounts of epithelial cadherin (ECAD)was measured in hDF and iRC cells grown in 2D
and 3D by Western blot. hESC were used as a positive control for ECAD, and actin was used 
as a loading control. (b) Immunohistochemistry for ECAD in hDF and iRC grown in aggregates, 
protein visualization done with DAB staining. Human skin was used as a positive control for 
ECAD staining. 
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HeLa cells. RT-PCR for α11 was done in ChoK1 cells for clone #6 (Figure 4.6b).  Cells transfected with 
α11-GFP were positive for Itga11 transcript, and interestingly Itgb1 as well. 
Figure 4.4.  Cloning of Itga11-CT-GFP  
(a) pENTR233.1-sfiI-a11 plasmid digested with SfiI enzyme to isolate Itga11 from plasmid. Lane 
1—2 log ladder, Lane 2—pENTR233.1-sfiI-a11 plasmid digest, Lane 3—uncut pENTR233.1-sfiI-
a11 control. (b) plasmid map for pcDNA3.1/CT-GFP-TOPO used for blunt ligation of Itgall into 
multiple cloning site. (c) Directional digestions to determine insert orientation in clones 1-13, 
digests marked in red indicate ligations inserted backwards, digests marked in green indicate 
clones inserted in the correct orientation.  
Figure 4.5 Over-expression of Itga11-CT-GFP 
(a) pCDNA3.1-itga11.ctGFP construct map (b) HeLa and CHO-K1 cells were transfected with 
pcDNA3.1-Itga11.gfp clones, and cell lysates were probed for protein by Western blot with anti-
integrin alpha 11 antibody. HeLa cells were live imaged at 40x. 
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This suggests that α11 somehow over-expression of α11 may be regulating the 
expression of Itgb1 transcript, however as we were interested in the role of α11, we did not 
follow this result (Figure 6a). In order to determine if we were making full-length protein, we ran 
Western blot analysis with anti-GFP primary antibody (Figure 4.6c). Also fluorescence imaging 
of HeLa cells confirmed expression and localization of α11-GFP (Figure 4.6d). 
The transfection efficiency in the HeLa and CHOK1 cells was low, both with lipid-based 
and electroporation-based transfection methods. The overall transfection efficiency we saw in 
these transformed lines was around 10-15% based on quantification of GFP-positive cells. 
Transfection attempts on hDF cells using lipofectamine as well as electroporation did not result 
in positively transfected cells. This could be as a result of hDF being a very difficult cell type to 
transfect combined with the relatively large plasmid size of 9.6kb. Given the limited population 
doubling number that hDF cells can undergo, it was not feasible to create a stably transfected 
cell line as hDF reach senescence before a stably transfected population could be established 
Figure 4.6 Knock-down of Itga11 
(a) RT-PCR for knock-down of Itga11 and Gapdh in hDF. (b) Western blot for a11 in hDF at 24, 
48 and 72 hours post transfection with siRNA. hESC used as a negative control, hDF used as a 
positive control. Actin was used as a loading control for Western blotting. (c) RT-PCR for genes 
associated with knockdown of a11, Actin used as a loading control, NTC indicates no template 
control.   
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so the over-expression of α11 could not be studied in hDF cells. 
Knock-down of Integrin alpha-11 
Due to the inability to create a stably transfected hDF line, an alternative route was 
followed to show the effect of lack of α11 expression. Transient knock-down experiments were 
performed in hDF using siRNA to Itga11 (Figure 4.7a). Using a commercially available siRNA 
against human α11 (ON-TARGETplus siRNA, Dharmacon, GE Healthcare) Itga11 was 
transiently knocked down in hDF. Transcript knock-down was validated by RT-PCR (Figure 
4.7a), and protein level was analyzed by Western blot (Figure 4.7b). Knock-down of α11 protein 
was confirmed as early as 24-hours and as late as 72-hours, and the knock-down hDF were 
assayed for changes in expression levels of Itga11, Gapdh, Rex1, Oct4, Mmp1 (Figure 4.7c). 
No major changes were observed in the five genes of the genes at 72-hours post knock down. 
Rex1 and Oct4 were chosen as early markers of both our defined culture system as well as 
MET. Additionally Mmp1 expression levels were analyzed as it was known that Mmp1 is 
transcriptionally up-regulated when cells are cultured using our defined culture conditions. No 
change in gene expression profile of hDF was seen after 72 hours of α11 knock-down. This may 
be due to the short transient knock-down (Figure 4.7d). 
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4.3 Conclusions 
Culturing hDF under our experimental culture conditions resulted in a shift away from 
collagen-I expression in iRC, however that did not appear to have an effect on overall cellular 
attachment as the vimentin-containing focal adhesions stained strongly, and the focal adhesion 
kinase (FAK) pathway remained active. qRT-PCR confirmed the up-regulation of several 
integrin α-subunits associated with attachment to ECM components present in basement 
membrane, and showed an up-regulation in gene expression that was consistent with MET.  
It was not possible to determine if integrin mediated signaling, through integrin alpha-11 
(α11) had a role in the MET associated transcriptional shift observed in iRC as the 
overexpression construct used did not express α11-GFP in hDF.  
Lack of ECAD expression a marker for late MET could be due to many factors, as MET 
requires a very complex set of molecular events, and it is likely that iRC have not undergone a 
complete transition. The observed gene expression dynamics consisting of three consecutive 
phases of reprogramming suggest that iRC may be in an early (initiation) phase of MET and in 
order for a full MET to occur, iRC might require exogenous forced factor expression in order to 
cross the threshold. Additionally, REX1 protein was not detectible by Western blot at day 30 and 
likely a contributing reason to why iRC could not move into the stabilization phase of MET even 
in 3D culture. Previous work has shown that other cell types have been observed to be 
incapable of going through MET using only cell culture techniques [36].  
Within EMT, epithelial and mesenchymal phenotypes are considered endpoints in the 
transition. The nature of a transition lends us the argument that intermediate phenotypes exist, 
and correspond to partial EMT/MET. This intermediate state has been observed in wound 
healing and has been hypothesized to allow for establishment of equilibrium through cells 
capable of easily switching between phenotypes [37]. Additionally, partial EMT/MET cells have 
been observed during development [38], cancer [39], and fibrosis [40]. Induction of stem cell 
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genes, through defined culture conditions may be forcing iRC into an intermediate phenotype 
characteristic of MET. 
MET is a well-defined mediator of pluripotency reprogramming and an established 
starting point for trans-differentiation. For example, it has been shown that a partial MET is 
useful in the direct reprogramming of mouse fibroblasts into cardiomyocites [41]. With this in 
consideration, we can speculate that early stages of MET might be useful in priming cells for 
direct reprogramming. Further work to characterize MET would be useful in determining the 
state of epigenetic changes in cells undergoing reprogramming. It is still not known whether 
MET is responsible for complete epigenetic changes in fibroblasts, or if they still retain prior 
epigenetic traits. A defined culture system as described here, which induces the beginning of 
MET may be useful in determining epigenetic state, which is thought to have implications on 
future differentiations depending on the cell source trying to be created via reprogramming [42].  
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5.0 Conclusions 
The work contained in the chapters of this thesis rely heavily on a body of data showing 
that relatively simple manipulation of a cell culture environment in vitro can lead to many 
changes in the gene expression profile of human dermal fibroblasts and the induction of stem 
cell genes (Oct4, Sox2, Nanog, Rex1 and Lin28) and increase the life span of human dermal 
fibroblasts (iRC). This culture system mediating these changes is characterized by reduced 
oxygen tension and the addition of exogenous FGF2.  Human dermal fibroblasts (hDF) cultured 
under those conditions exhibit some molecular characteristics of pluripotent cells; however they 
do not acquire pluripotency and they do not form tumors when injected into SCID mice. One 
major characteristic of our in vitro culture system is the induction of an extended lifespan. In 
addition, human muscle derived fibroblasts cultured under the aforementioned conditions 
contribute to the regeneration of mouse skeletal muscle through functional engraftment and 
acquisition of a PAX7 positive satellite cell phenotype. FGF2 appears to be the critical 
component to this system [1, 2]. 
In chapter one, we tested the hypothesis that FGF2 signaling under low oxygen 
conditions induces changes in the expression of extracellular matrix and adhesion molecules 
that reflect the transition in their developmental potential – namely, a departure from producing 
predominantly collagen-based environment. A large number of molecular cues  occur through 
the extracellular niche, therefore we hypothesized that the role of the extracellular environment 
on stem cell behavior in vitro is critically important for maintenance of pluripotency. We have 
found an overall deregulated extracellular matrix and integrin profile in human dermal 
fibroblasts grown in low oxygen with FGF2 supplementation (iRC). In this work we defined the 
overall changes in the composition ECM and in the integrin profile in human dermal fibroblasts. 
An ECM/AM microarray was used as an initial screen and out of 96 potential targets 25 were 
determined to be present in hDF and iRC cells.  
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 Out of those 25 targets, 15 were highly deregulated and were subject to further analysis 
by qRT-PCR. From the 15 targets chosen, we were able to characterize iRC by a change in 
niche dynamics defined by the most highly deregulated targets belonging to a similar ontology.  
A 17-fold down-regulation in Itga11 (collagen-I attachment) transcript and a 5-fold MMP1 
(collagenase type-I) up-regulation led us to believe the iRC cells were remodeling the niche to 
remove collagen-I and subsequently, adhere to non-collagen-I substrate. By western blot, we 
showed that COLI was lost from iRC cultures, as well as integrin alpha-11. Additional qRT-PCR 
analysis for alternate integrin alpha and beta subunits led us by subtractive analysis to 
determine that iRC cultures were likely adherent to RGD and laminin substrates, which were 
indicative of a niche with basement membrane components. A fibroblast phenotype which no 
longer synthesizes and anchors to collagen-I characterizes a fibroblast phenotype that is able to 
participate in wound healing with a less fibrotic response.  
In chapter two we tested the hypothesis that low oxygen-mediated FGF2 signaling is 
suppressing transcriptional activity of integrin α11 either directly or indirectly. In this chapter we 
investigated the mechanism of a collagen-I binding integrin α11 (ITGA11) down-regulation in 
response to low oxygen-mediated FGF2 activity. We described a significant down-regulation of 
ITGA11 and showed that it’s loss requires FGF2 induced ERK1/2 activity. Moreover in the 
presence of FGF2, ITGA11 expression could not be rescued by TGF-β1, a potent activator of 
ITGA11. This indicated that ERK1/2 mediated FGF2 down-regulation of α11 by suppressing 
TGF-β1 activity. We also showed that FGF2 is capable of overriding TGF-β1 mediated alpha-
smooth muscle actin expression, a marker of pro-fibrotic activated fibroblasts.   
In chapter three we tested the hypothesis that the transition between a fibroblast and an 
induced regeneration competent cell proceeds through a mesenchymal-to-epithelial transition 
(MET), and that this transition is a consequence of down-regulation of α11. 
In chapter three we characterize the presence of focal adhesions and focal adhesion 
kinase activity in iRC’s, and identify activation of expression of initiation stage MET genes. 
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These observations indicate that the activation of MET initiation stages may require a shift in 
extracellular matrix and adhesion molecules. We attempted to confirm a regulatory role for α11 
in this transition, but could not achieve over-expression of α11. Similarly, the knock-down 
studies of α11 through transient transfection remain inconclusive. To facilitate MET, we 
aggregated and subsequently culture iRC in 3D aggregates. We show by Western blot and 
immunostaining that aggregates do not express epithelial cadherin, which is a defining marker 
for epithelial phenotype. The completion of MET with acquisition of an epithelial phenotype is 
necessary for induction of pluripotency, however further understanding the mechanism of a 
partial transition may lead to development of cell phenotypes for therapy without the associated 
risk of tumor formation.  
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Figure 5.1 Model Diagram of Thesis Conclusions 
Human dermal fibroblasts (hDF) when cultured without exogenous FGF2 express 
integrin alpha-11 and collagen-I extracellular matrix protein. When hDF are exposed to 
low-oxygen (5%) and FGF2, they increase production of MMP1, and show an overall 
down-regulation in α11 protein from focal adhesions, hDF undergoing this phenotype 
switch are thought to be undergoing acquisition of induced regeneration competence 
(iRC). When FGF2 is added to hDF, they activate phosphorylation of ERK1/2. Activated 
ERK1/2 is mediating the loss of α11 from hDF as demonstrated by use of ERK inhibitor 
U0126. After blocking ERK1/2 phosphorylation, hDF express α11 protein even in the 
presence of exogenous FGF2 (iRC). This transition is also marked by an up-regulation 
of epithelial cadherin transcript (Ecad) and a down regulation in expression of 
transcription factor Snail (Snail). These two transcriptional changes are known to be 
involved in the initiation phase of Mesenchymal-to-Epithelial transition in induction of 
pluripotency. We believe the iRC phenotype we observe is an early stage initiation 
phase of MET, and that if given additional biological cues may be able to complete the 
MET transition required for complete reprogramming.   
This work has immediate potential applications in fibrosis and wound healing. We know 
that after injury, fibroblasts replace the wound with granulation tissue, composed of fibronectin 
and collagen-I and the wound is re-vascularized. In addition, fibroblasts acquire an activated, 
highly contractile phenotype to close the wound with deposition of collagen-I dense scar tissue. 
Subsequent to wound closure, remodeling events usually occur, which should revert collagen-I 
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dense scar tissue into functional tissue architecture [3]. In extreme cases when the routine 
healing process is compromised due to severe trauma, or upon deregulation normal 
fibrotic/healing response; irreversible fibrosis occurs, resulting in deposition of excessive fibrous 
connective tissue and dense scar formation. Additionally, pathological fibrosis can have 
implications beyond scar formation. Fibrotic pathologies compromise the function of affected 
organs and tissues. Irreversible fibrosis is frequently responsible for death from end-stage liver, 
kidney, heart diseases, idiopathic pulmonary fibrosis [4] and unresolved fibrotic conditions are 
features of many autoimmune diseases [5]. TGFβ-1 mediates these fibrotic responses [6] 
through activation of ECM genes [7] and suppression of regulators of ECM degradation [8]. In 
fibrotic conditions, activated fibroblasts deposit large amounts of collagen-I by TGF-β1 [9]. A 
feature that is common to the majority of fibrotic conditions regardless of initiating events is the 
activation of fibroblasts to a myofibroblastic phenotype that in many diseases are thought to be 
largely responsible for the deposition of extracellular matrix ultimately resulting in fibrosis. 
Currently, choric fibrosis is irreversible [10]. Therapies to reverse, stop or make any 
improvement to an existing fibrotic tissue, or even to reverse existing tissue fibrosis are scarce. 
The presentation of fibrotic conditions in many organs are pathologically similar, therefore using 
a common tissue fibrosis pathway could yield therapeutic targets for other presentations.  
 Fibrosis is not just limited to wound healing, it is defined as a scarring process involving 
excessive deposition of extracellular matrix (ECM) and leading to impairment of organ function. 
Progression and worsening of chronic diseases of the liver, kidney [11], heart [12], and lung [13] 
have been associated with fibrosis. Fibrosis also plays a role in the skin pathologies such as 
scleroderma [14], inflammatory bowel disease [15] and bone marrow myelodysplastic 
syndromes [16].   
Additionally, the stroma of solid tumors can be considered fibrotic tissue [10]. It has been 
recently extensively shown that wound-healing, fibrosis and cancer share common biological 
processes [10], and that the tumor niche resembles a site of chronic wound healing [17]. Of 
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many similarities between wound healing and tumor progression, the mutual presence of 
myofibroblastic cells has emerged as a common hallmark [18].  
Integrin-α11 has been described as contributing factor to fibrotic tumor stroma [19]. In 
many cases, fibrotic tumors are chemotherapy resistant, one reason being that they are highly 
dense, and impermeable cytotoxic chemotherapy [20]. Cancer-associated fibroblasts 
contribute heavily to all stages of cancer, and are an emerging target for therapy due to their 
participation in fibrous tumor stroma [9]. α11 contributes to this dense environment through 
high levels of binding to collagen-I [19]. Mitigation of α11 biding through a pathway 
independent of TGFβ-1 could provide therapeutic targets for dense fibrotic tumor stroma. 
The “pro-regenerative” phenotype we observe with iRC cells is capable of triggering a 
non-fibrotic response in dermal fibroblasts, independent of TGFβ1 mediated fibrotic response. 
As both TGFβ1 and FGF2 are present in the wound site and in tumors, it is likely that we are 
describing a physiological dynamic relationship which we hypothesize can be manipulated to 
address a variety of applications. 
In summary, this human fibroblast conversion system allows for a cell-fate conversion 
from an abundant cell source to a more ‘developmentally’ plastic cell type. This phenotype has 
the potential for therapeutic applications in regenerative medicine, and moreover the ability to 
overcome the limitation of reaching a number of cells which could be useful for therapy. 
Identification of molecular mechanisms controlling this phenotype conversion has the potential 
to transition this system to other cell sources, which would broaden the range of therapeutic 
possibilities for autologous cell therapy. 
117 
5.1 References 
1. Page RL, Ambady S, Holmes WF, Vilner L, Kole D, Kashpur O, Huntress V, Vojtic I,
Whitton H, Dominko T: Induction of stem cell gene expression in adult human
fibroblasts without transgenes. Cloning Stem Cells 2009, 11(3):417-426.
2. Page RL, Malcuit C, Vilner L, Vojtic I, Shaw S, Hedblom E, Hu J, Pins GD, Rolle MW,
Dominko T: Restoration of skeletal muscle defects with adult human cells
delivered on fibrin microthreads. Tissue engineering Part A 2011, 17(21-22):2629-
2640. 
3. Clark RAF: The molecular and cellular biology of wound repair, 2nd edn. New York:
Plenum Press; 1996.
4. Gabbiani G: The myofibroblast in wound healing and fibrocontractive diseases.
The Journal of pathology 2003, 200(4):500-503.
5. Szabo E, Rampalli S, Risueno RM, Schnerch A, Mitchell R, Fiebig-Comyn A, Levadoux-
Martin M, Bhatia M: Direct conversion of human fibroblasts to multilineage blood
progenitors. Nature 2010, 468(7323):521-U191.
6. Mauviel A: Transforming growth factor-beta: a key mediator of fibrosis. Methods in
molecular medicine 2005, 117:69-80.
7. Varga J, Jimenez SA: Stimulation of normal human fibroblast collagen production
and processing by transforming growth factor-beta. Biochemical and biophysical
research communications 1986, 138(2):974-980.
8. Overall CM, Wrana JL, Sodek J: Independent regulation of collagenase, 72-kDa
progelatinase, and metalloendoproteinase inhibitor expression in human
fibroblasts by transforming growth factor-beta. J Biol Chem 1989, 264(3):1860-
1869. 
9. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nature reviews Cancer 2006, 6(5):392-
401. 
10. Brad R, Janusz F-B, Edna C: The wound healing, chronic fibrosis, and cancer
progression triad. Physiological genomics 2014, 46(7):223244.
11. Lan HY: Diverse roles of TGF-β/Smads in renal fibrosis and inflammation.
International journal of biological sciences 2010, 7(7):1056-1067.
12. Song K, Nam YJ, Luo X, Qi X, Tan W, Huang GN, Acharya A, Smith CL, Tallquist MD,
Neilson EG et al: Heart repair by reprogramming non-myocytes with cardiac
transcription factors. Nature 2012, 485(7400):599-604.
13. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J: Adenovector-mediated gene
transfer of active transforming growth factor-beta 1 induces prolonged severe
fibrosis in rat lung. Journal of Clinical Investigation 1997, 100(4):768-776.
14. Leask A: Transcriptional profiling of the scleroderma fibroblast reveals a potential
role for connective tissue growth factor (CTGF) in pathological fibrosis. The Keio
journal of medicine 2004, 53(2):74-77.
15. Lennard-Jones J: Classification of inflammatory bowel disease. Scandinavian
Journal of Gastroenterology 1989, 24(S170):2-6.
16. Lambertenghi‐Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D: Myelodysplastic
syndrome with increased marrow fibrosis: a distinct clinico‐pathological entity.
British journal of haematology 1991, 78(2):161-166.
17. Dvorak HF, Flier J, Frank H: TUMORS - WOUNDS THAT DO NOT HEAL -
SIMILARITIES BETWEEN TUMOR STROMA GENERATION AND WOUND-HEALING.
New England Journal of Medicine 1986, 315(26):1650-1659.
118 
18. Cirri P, Chiarugi P: Cancer associated fibroblasts: the dark side of the coin.
American journal of cancer research 2011, 1(4):482.
19. Lu N, Karlsen TV, Reed RK, Kusche-Gullberg M, Gullberg D: Fibroblast alpha11beta1
integrin regulates tensional homeostasis in fibroblast/A549 carcinoma
heterospheroids. PLoS One 2014, 9(7):e103173.
20. Park MS, Araujo DM: New insights into the hemangiopericytoma/solitary fibrous
tumor spectrum of tumors. Curr Opin Oncol 2009, 21(4):327-331.
119 
Chapter 6 
Future Directions 
120 
6.0 Immediate Future Directions 
This thesis describes an overall shift in extracellular matrix and adhesion molecules 
gene expression in human dermal fibroblasts undergoing the initiation phase of Mesenchymal to 
Epithelial Transition during conversion to induced regeneration competent cell phenotype. This 
transition is marked by a loss of α11 and its binding partner Collagen-I through a mechanism 
that is mediated by ERK1/2 activation and suppression of TGF-β1-mediated regulation of α11. 
Additionally, a shift in the transcript levels of other adhesion molecules demonstrate that iRC 
cells are most likely transitioning to attachment to a laminin and fibronectin-based matrix, 
suggesting that they may be producing a more “pro-regenerative matrix”. We hypothesized that 
the shift in the cells ECM production and interaction with ECM serves as a feedback loop during 
the phenotype shift, as contact with extracellular matrix and its involvement in the regulation of 
potency in adult stem cells within the niche has been demonstrated extensively. We anticipate 
that this “pro-regenerative” shift can be exploited in wound healing biology and fibrosis research, 
as it triggers a non-fibrotic response in dermal fibroblasts, overriding TGFβ1-mediated fibrotic 
response since both TGFβ1 and FGF2 are present at the wound site. Manipulation of the 
dynamic relationship between the two could be used to reduce scar deposition. 
Immediate directions for follow-up studies include (1) determining the FGF2 responsive 
elements through promoter analysis, (2) elucidating a role of FAK in the regulation of α11.  
Determine FGF2 responsive elements through promoter analysis 
In order to determine factors that may be regulating Itga11 transcription, the promoter 
regions of the 15 most highly deregulated genes from the ECM/AM array were compared (data 
not shown).  The Transcription Factor Matrix Explorer (TFM-Explorer) [1] was used to analyze 
regulatory regions in eukaryotic genomes and assess conservation of spatial arrangements of 
regulatory elements. The algorithm works through two steps, 1) by scanning the sequences for 
all potential transcription factor-binding sites. For this comparison we used both the TRANSFAC 
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and JASPAR motifs databases, and 2) by extracting significant clusters and calculating a p-
value. When the 15 highly deregulated genes were compared for common transcription factor 
elements, we determined that they all have SP1 transcription factor in common as a regulatory 
element.  
For future work, it would be important to investigate the potential role of Sp1 in the 
regulation of integrin-alpha 11, and additionally investigate the potential for HLTF-1 in this 
process. Sp1 is able to activate transcription through association with a co-activator associated 
with TATA-box binding transcription factors. Sp1 is implicated in recruitment of TATA-binding 
protein and subsequent facilitation of the transcription initiation complex to the start site [2] even 
in cases of genes lacking a TATA-box [3]. When Sp1 was blocked by anti-sense Sp1 
fibroblasts, they showed reduced expression of extracellular matrix associated genes [4], 
therefore it is likely that an interference with Sp1 binding to integrin alpha -11 promoter may be 
involved in regulation of it’s expression. Additionally, α11 transcription has been shown to be 
mediated by TGF-β1 in a Smad2/3 and Sp1 dependent manner [5, 6]. 
In order to further elucidate what the regulatory mechanism between ERK1/2 and 
integrin-alpha 11 might be, we mapped common regulatory elements between α11 and α-sma 
as they both have been implicated in fibrosis and are regulated by Sp1. When they were 
compared (data not shown), they showed a common regulatory element, Helicase-like 
transcription factor (HLTF1). HLTF-1 has been shown to interact with SP1 and SP3 
independently of DNA; the interaction with these transcriptional factors may be required for 
basal transcription of target genes [7].  
Another potential regulatory mechanism for the down-regulation of integrin alpha-11 may 
be through activation of Vitamin D3 (VD3). A recent study looking at RUNX and VD3 in 
combination showed that integrin alpha-11 expression could be up-regulated by RUNX, but 
when VD3 was introduced in the presence of RUNX, integrin-alpha 11 transcript was decreased 
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[8]. Smad proteins have been shown to cross talk with several other transcription factors, and 
regulatory elements, such as vitamin D3 (VD3), TFE3 and Sp1 to activate transcription [9]. 
 This would be a pathway of interest to more fully understand this process, as VD3 has 
been shown to be activated by MAPK signaling and additionally, its activation has also been 
shown to increase epithelial cadherin expression [10].  
Elucidate role for FAK in FGF2 mediated down-regulation of Integrin alpha-11 
It has been shown that FAK is necessary for the FGF2 mediated down-regulation of α-
sma, however FAK does not contribute to a TGFβ -dependent a myofibroblast phenotype [11, 
12].  In the same study, FGF2 mediated signaling through ERK was shown to be dependent on 
FAK, however the regulation of this process is unknown [11]. It is thought that the relationship 
between FAK and FGF2 mediates the reversal of fibrotic phenotype and could be a a potential 
target for treatment of fibrotic pathology [13].  
With the hypothesis that FGF2 is mediates α11 expression in a similar mechanism to its 
regulation of α-sma, the role for FAK in this process may provide insight as to how FGF2 
signaling regulates integrin-alpha 11 expression in the presence of TGF-β1.   
For future work, it would be of interest to investigate the pathway by which FGF2 
activates FAK to induce an anti-fibrotic response in the presence of TGF-β1. If FAK signaling is 
directly involved in the FGF2 mediated down-regulation of fibrotic related pathways, such as the 
expression of α-sma, it may also be playing a role in the FGF2-mediated down-regulation of 
integrin alpha-11.  
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Chapter 7 
Materials and Methods 
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7.1 Chapter 2 
Cell culture 
Primary adult human dermal fibroblasts (CRL-2352) were obtained from 
American Tissue Culture Collection (ATCC; Manassas, VA). Cells were cultured in 
DMEM:Ham’s F12 (v:v), supplemented with 10% Fetal Clone III (Hyclone, USA), 4 mM 
L-glutamine at 37˚C, 5% CO2, and 5% O2. Cells were passaged at 80% confluence 
using standard procedures. When used, human recombinant FGF2 (Peperotech, 
Rockyhill, New Jersey) was supplemented at 4 ng/mL.  Human embryonic stem cells - 
hESCs (H9, WiCell, Madison, WI) were cultured on primary mouse embryonic fibroblasts 
(MEFs) derived from E13-E14 mice, and used up to passage 7. Mitomycin-C inactivated 
MEFs were plated at a density of 2.25 x 104 cells/cm2 on tissue culture plates coated with 
1% gelatin solution (MP Biologicals, Solon, OH). hESCs were plated onto inactivated 
MEFs and cultured in Knockout DMEM (Life Technologies, Carlsbad CA), supplemented 
with 15% Knockout serum (Life Technologies, Carlsbad CA), 2.0 mM Glutamax (Life 
Technologies, Carlsbad CA), 50 mM 2-β-mercaptoethanol (Sigma-Aldrich, St. Louis, 
MO), 1x MEM non-essential amino acids (Mediatech, Manassas, VA) and 4 ng/mL FGF2 
(Peprotech, Rocky Hill, NJ) in 5% oxygen. Medium was changed daily except for the first 
day after plating to allow hESCs to attach. Cells were passaged every five days.  hESC 
colonies were dissociated using enzyme-free Cell Dissociation Buffer (Life Technologies, 
Carlsbad CA) and split 1:12 onto new MEFs feeder layer prepared as described 
previously. 
ECM/AM Array: 
A human pathway-focused oligo hybridization microarray for ECM and adhesion 
molecule (AM) targets (SA Bioscience Corp., Frederick, MD) was used to determine 
screen for change in transcript expression between hDF and iRC. The array contained 
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96 ECM/AM targets. RNA samples from both hDF and iRC was isolated as described for 
RT-PCR. RNA samples were labeled and amplified. cRNA was applied to each array 
and hybridized overnight at 60°C. Positive cRNA binding was detected by incubation 
with a chemilluminescent substrate, CDP-Star (Super Array). Images for the array 
membranes were acquired using a Gel Doc XR™ System (Bio-Rad, Hercules, CA). The 
images were exported at the highest resolution, and analyzed using GEArray Expression 
Analysis Suite Software (GEArray). 
RT-PCR 
RNA from cells was extracted using TRIzol reagent (Life Technologies, Carlsbad, 
CA) according to the manufacturer’s protocol and the concentration determined with 
Nanodrop 2000 using A260/A280 ratio between 1.9 and 2.0 (Thermo Scientific, Waltham 
MA). Isolated RNA was incubated with DNase to remove any contamination with 
genomic DNA following the manufacturer’s protocol (Agilent Technologies, Santa Clara, 
CA). One microgram of RNA was reverse transcribed using qScriptTM cDNA Synthesis 
Kit (Quanta Biosciences, Gaithersburg, MD). RT-PCR was performed using GoTaq® 
green master mix (Promega, Madison, WI). All RT-PCR reactions were set as follows: 
20 µL reaction volume, 50 ng of cDNA template, 200 nM forward and reverse primers 
(Table 1). PCR was run with an initial denaturation at 95°C for 7 minutes followed by 28 
cycles of the following sequence: denaturation at 95°C for 30 seconds, annealing for 30 
seconds (primer-specific temperature), extension at 72°C for 20 seconds followed by a 
clean-up extension at 72°C for 7 minutes. RT-PCR products were resolved on 1% 
agarose gels containing 0.5µg/ml ethidium bromide in TAE buffer. Images were obtained 
on a BioRad Gel Doc™ XR system (BioRad, Hercules, CA). No template and no reverse 
transcriptase reactions were used as controls. 
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qRT-PCR 
For qRT-PCT, RNA was extracted using the protocol described in RT-PCR 
methods. SYBR® Green Real Time PCR Master Mix (Life Technologies, Carlsbad, CA) 
was used as an indicator dye, with ROX as a passive dye. For each 20µL reaction, 40ng 
of template cDNA was used. Controls run in parallel were no-template and no-reverse 
transcriptase. All qPCR reactions were performed in experimental triplicates and 
subsequent values were combined to calculate average cycle threshold (Ct). Signal was 
measured using the 7500 Real Time PCR system (Applied Biosystems, Bedford, MA). 
Expression profiles for transcripts were calculated by the delta delta-Ct method [1] and 
normalization to delta-CT of actin. Expression profiles are represented as fold change in 
expression using the delta-delta CT method. Fold change in expression less than one is 
expressed as the negative inverse to account for directionality. In order to quantify the 
amount of miRNA29a, total small RNA was isolated from cells using NucleoSpin® 
miRNA kit following manufacturer instructions (Macherey-Nagle, Duren, Germany). Total 
miRNA quantification was performed using qScript microRNA Quantification System 
(Quanta Biosciences, Gaithersburg, MD). miRNA cDNA was synthesized from 1 µg of 
RNA using qScript microRNA cDNA synthesis kit (Quanta Biosciences, Gaithersburg, 
MD). qPCR reactions were performed on a 7500 Real Time PCR system (Applied 
Biosystems, Bedford, MA). Cycling was peformed as follows: 40 cycles at 95°C for 5 
seconds and at 60° C for 30 seconds. PerfectCTa microRNA Assay qPCR primers were 
used for miRNA29a, miRNA29b, and RNU6 miRNA was used as a positive control for 
normalization. The specificity of primers was monitored with heat dissociation at the end 
of the run. All expression levels were calculated using the delta delta-Ct method [1].  
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Western blotting 
Total protein was isolated from cells using cold lysis buffer (40 mM Tris-HCl, 250 
mM NaCl, 8% glycerol, 0.0125% Brij-35, 0.01% Triton X-100, 0.005% Tween-20) 
supplemented with complete protease inhibitor cocktail (Roche, Basal, CH). Cells were 
lysed on ice using a Missonix XL-2000 ultrasonic cell disruptor for 3 x 10 pulses at power 
2. Total cell lysate was mixed with 5X Laemmli sample buffer. Samples were boiled for 5
minutes and separated on 4-20% SDS-PAGE gels (Bio-Rad). For Western blot analysis, 
protein was transferred to PVDF membrane (Millipore, Billerica, MA) using a semi-dry 
transfer apparatus (GE Healthcare, Fairfield, CT). Membrane was blocked in TBS-T 
buffer (25 mM Tris-HCl pH7.5, 130 mM NaCl, 0.1% Tween-20) with 5% fat-free dry milk 
for 30 minutes. The membrane was incubated overnight with 1% fat-free dry milk at 4˚C 
with primary antibodies: anti-ITGA11 (MAB4235, 1:500, RD Systems), anti-TGFβ1 
(9758, 1:500, Abcam), anti-COLIA1 (sc-8783, 1:500, Santa Cruz), anti-Fibronectin (sc-
9068, 1:500, Santa Cruz), anti-p44/42 MAPK (Erk1/2) (4695, 1:1000, Cell Signaling 
Technologies), anti- Phospho-p44/42 MAPK (Erk1/2) (4370, 1:1000, Cell Signaling 
Technologies), anti-FAK (13009, 1:500, Cell Signaling Technologies), anti-Phospho-FAK 
(Tyr397) (8556, 1:500, Cell Signaling Technologies), anti-Phospho-FAK (Tyr576/577) 
(3281, 1:500, Cell Signaling Technologies), anti-Phospho-FAK (Tyr925) (3284, 1:500, 
Cell Signaling Technologies). After washing the membrane 3 x 10 minutes in TBS-T, the 
membrane was incubated for 2 hours at room temperature in appropriate HRP-
conjugated secondary antibodies (BioRad, Hercules, CA) . The bands were visualized 
using a Gel Doc XR™ System (Bio-Rad). 
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7.2 Chapter 3 
Cell culture 
Primary adult human dermal fibroblasts (CRL-2352) were cultured as indicated in 
previously in chapter 2 materials and methods. When indicated, human dermal 
fibroblasts were incubated with 10ug/mL alpha-amanatin to block new transcription. 
When indicated, dermal fibroblasts were stimulated with TGFβ1 at concentrations 
ranging from 0.05 to 50 ng/mL. Cultures were treated with TGFβ1 for seven days in 
parallel with FGF2 supplemented cultures. For ERK inhibitor studies, cells were seeded 
at a density of 5000 cells / cm^2 in order to have sufficient material for harvest. Cells 
were serum starved and, when noted, treated with ERK1/2 inhibitor (U0126) (Cell 
Signaling Technologies, MA) at 80ug/mL for 2 hours. After incubation, medium was 
replenished with complete medium for each variable, which was supplemented with 
FGF2, U0126 or a combination. Cells were allowed to grow for 72 hours and then 
harvested for analysis. When assaying for ERK1/2 activation, cells were treated as 
above and harvested 1 hour after being returned to complete medium in order to verify 
that ERK1/2 phosphorylation had been blocked sufficiently. 
RT-PCR and RT-qPCR analysis 
All RNA, RT-PCR and RT-qPCR were performed as described previously in 
chapter 2 materials and methods. In order to quantify the amount of miRNA29a, total 
small RNA was isolated from cells using NucleoSpin® miRNA kit following manufacturer 
instructions (Macherey-Nagle, Duren, Germany). Total miRNA quantification was 
performed using qScript microRNA Quantification System (Quanta Biosciences, 
Gaithersburg, MD). miRNA cDNA was synthesized from 1 µg of RNA using qScript 
microRNA cDNA synthesis kit (Quanta Biosciences, Gaithersburg, MD). qPCR reactions 
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were performed on a 7500 Real Time PCR system (Applied Biosystems, Bedford, MA). 
Cycling was peformed as follows: 40 cycles at 95°C for 5 seconds and at 60° C for 30 
seconds. PerfectCTa microRNA Assay qPCR primers were used for miRNA29a, 
miRNA29b, and RNU6 miRNA was used as a positive control for normalization. The 
specificity of primers was monitored with heat dissociation at the end of the run. All 
expression levels were calculated using the delta delta-Ct method [1]. 
Immunocytochemistry: 
Fibroblasts were grown on glass coverslips for immunostaining. Cells were fixed 
with ice-cold methanol or 2% methanol-free formaldehyde. Samples were permeabilized 
with 1M HCl or 0.1 % TritonX-100, respectively. Samples were blocked with 5% bovine 
serum albumin (BSA) in Tris-buffered saline with 0.1% Tween-20 (TBS-T, 25 mM Tris-
HCl pH 7.5, 130 mM NaCl, 0.1 % Tween-20). Primary antibodies were diluted in TBS-T 
supplemented with 1 % BSA. Cells were labeled for 2 hours at room temperature. Plates 
were washed three times with TBS-T and secondary antibodies conjugated to either 
AlexaFluo-568, or AlexaFlour-488 (Invitrogen, Carlsbad CA) diluted in TBS-T with 1 % 
BSA for 1 hour. Coverslips were mounted using Prolong Gold® (Invitrogen, Carlsbad 
CA). Incubation with secondary antibody alone and rabbit IgG were used as negative 
controls. Images were acquired using confocal microscopy at identical settings. 
DNA methylation analysis 
The following assay was developed as a modification of [2]. Genomic DNA was 
purified using Quick-gDNA™ MiniPrep (Zymo Research, Irvine, CA). DNA was 
quantified with Nanodrop 2000 using an A260/A280 ratio (Thermo Scientific, Waltham, 
MA). To determine the genomic locations of CpG islands within integrin alpha-11 
promoter, the Transcriptional Regulatory Element Database was used, and CpG islands 
were mapped using MethPrimer software. Tiling primers were designed within the two 
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CpG islands mapped within the promoter region of integrin alpha-11 using NCBI Primer 
Blast. Control genomic DNA (New England Biolabs, Ipswich MA) was used in addition to 
DNA from experimental treatments. One hundred nanograms of total DNA was 
subjected to either a methylation-sensitive restriction enzyme (MSRE), methylation-
dependent restriction enzyme (MDRE) or a sham digest. Enzymes used were HhaI 
(MSRE) and McrBC (MDRE) (New England Biolabs, Ipswich MA). After digestion, DNA 
samples were cleaned over NucleoSpin® gDNA Clean-up XS (Macherey-Nagle, Duren, 
Germany). PCR for each primer pair was run on each digestion, genomic control DNA 
and a sham digestion. PCR was performed using GoTaq® green master mix (Promega, 
Madison WI). All PCR reactions were set as follows: 20uL reaction volume, 50 ng of 
DNA template, 200 nM forward and reverse primers each. PCR program was run with an 
initial denaturation at 95°C for 7 minutes followed by 28 cycles of the following 
sequence: denaturation at 95°C for 30 seconds, annealing 30 seconds (primer-specific 
temperature), extension at 72°C for 20 seconds, and a clean-up extension at 72°C for 7 
minutes. A no template control was run in parallel. PCR products were resolved on 2% 
agarose gels containing 0.5 µg/ml ethidium bromide in TAE buffer. Images were 
acquired with a BioRad Gel Doc™ XR system (BioRad, Hercules CA). 
Western blotting 
Western blotting was performed as described previously in chapter 2. Where 
indicated, membranes were probed with primary antibodies: anti-ITGA11 (MAB4235, 
1:500, RD Systems), anti-TGFβ1 (9758, 1:500, Abcam), anti-p44/42 MAPK (Erk1/2) 
(4695, 1:1000, Cell Signaling Technologies), anti- Phospho-p44/42 MAPK (Erk1/2) 
(4370, 1:1000, Cell Signaling Technologies), anti-actin (A2066, 1:10,000, Sigma). 
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7.3 Chapter 4 
Cell culture 
Primary adult human dermal fibroblasts (CRL-2352) were cultured as indicated in 
previously in chapter 2 materials and methods. Where indicated iRC cells were 
subjected to forced aggregation to try to achieve an epithelial phenotype. iRC cells were 
cultured in 2D for seven days, and subsequently transferred to low attachment culture 
dishes (Corning) where they were cultured for an additional three days. Cells were then 
transferred to hanging drops, and aggregates were formed in 20uL at 4000 cells per 
aggregate. Cells were then cultured statically for 2 days for aggregation to take place, 
and were subsequently transferred to low attachment plates for an additional 14 days. 
Aggregates were assayed at day 7 and day 14 for epithelial markers (Figure 7.1).  
Figure 7.1 A schematic showing how cells were transitioned from 2D to 3D 
culture Methods based on Corwin et al., 2007.
ITGA11 Cloning 
Itga11 cDNA (clone ID HsCD00295137) construct was purchased from Harvard 
Plasmid Repository. cDNA clone was in a pENTR223.1 Gateway cloning vector (Figure 
4.6a). Primers were designed to amplify itga11 cDNA for subcloning into a pcDNA3.1-
CT-GFP-TOPO® vector (Invitrogen) (Figure 4.2b). In order to assure expression of GFP 
tagged α11 it was necessary to introduce a point mutation to interrupt the stop codon. 
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Due to high GC content, and amplicon length LongAmp Taq (New England Biolabs) was 
used.  Ligation into pcDNA3.1-CT-GFP-TOPO requires 3’ deoxyribose adinine (dA) 
overhangs which are sometimes lost with high fidelity enzymes, addition of dA 
overhangs was done using Taq DNA polymerase (New England Biolabs) and dATP 
incubated at 72°C for 20 minutes. 
Ligations were transformed into E.coli One Shot® TOP10 Competent cells. 
Positive transformants were selected with 100µg/mL ampicillin.  Colonies were grown for 
16-18 hours, selected and grown in LB broth containing 100µg/mL ampicillin. Plasmid 
was isolated using a NucleoSpin® Plasmid isolation kit. pCDNA3.1-Itgα11-GFP was 
sequenced and insert orientation verified using restriction digestion at SmaI and BglII 
sites (Figure 4.6c). Colonies selected for proper insert orientation were clones 6 and 12 
(Figure 4.6c) and subjected to sequencing using M13 forward and M13 reverse 
sequencing primers. Sequencing results were analyzed using the basic local alignment 
tool (BLAST) on the on the national center for biotechnology information (NCBI) website, 
against the human cDNA library to determine sequence identity and verify the accuracy 
of stop codon PCR-based mutagenosis. 
Transfection 
Expression verification was performed in HeLa and CHO-K1 cells with transient 
(24-48 hour) and transfections using lipofectamine 2000 (Invitrogen) with endotoxin free 
plasmid DNA. RT-PCR, Western blot and live imaging techniques were used to verify 
expression and localization Itgα11-GFP. Cells were grown in 10cm tissue culture dishes 
to 70% confluence prior to transfection with pCDNA3.1-Itgα11-GFP isoforms. 
pCDNA3.1-Itgα11-GFP were transfected in cells using Lipofectamine® 2000 (Life 
technologies). Cells were incubated with lipofectamine/plasmid DNA in 50/50 DMEM 
(Hyclone), Ham’s F12 (Hyclone), 10% FBS (Hyclone) for 18 hours then fresh media was 
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added to the cells. Cells were harvested and subjected to Western blot analysis and 
chromatin immunoprecipitation 48 hours post transfection. Adult human dermal 
fibroblasts CRL2352 (ATCC) were also grown in 10cm tissue culture dishes at 80% 
confluency prior to transfection with individual FGF2 isoforms. Cells were incubated in 
50/50 DMEM (Hyclone), Ham’s F12 (Hyclone), 10% Fetal Clone III (Hyclone) with 
lipofectamine/plasmid DNA using the same expression vectors described above. Media 
were replaced with fresh growth media 8 hours post transfection. Western blot, RT-PCR 
and live imaging were used to verify expression and localization Itgα11-GFP. 
For human dermal fibroblast transfection, cells were electroporated with 
endotoxin free plasmid DNA. Approximately 1x106 cells were electroporated in 100 µl of 
electroporation buffer with three pulses with 10 seconds rest between each pulse at 
112mV for 1 msec/pulse (BTX). Electroporated cells were resuspended in complete 
medium. Western blot, RT-PCR and live imaging was used to verify the expression and 
localization of Itgα11-GFP. 
RT-PCR and RT-qPCR analysis 
All RNA, RT-PCR and RT-qPCR were performed as previously described in 
chapter 2 materials and methods. 
Immunohistochemistry 
Cell aggregates were washed in PBS and fixed in 2% paraformaldehyde for 2 
hours, rinsed with PBS and processed through alcohols, cleared in xylenes, embedded 
in paraffin wax, sectioned into 5µm slices, and mounted onto charged microscope slides. 
Paraffin wax was removed from the tissue sections by 3 incubations in Xylene, followed 
by hydration in graded alcohols and a 5-minute wash in diH2-O. Antigen retrieval was 
conducted in a pressure cooker for 20 minutes in a citrate-based antigen retrieval 
solution at a 1:100 dilution in diH2-O (Vector Labs). Incubating tissue sections in 3% 
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hydrogen peroxide for 15 minutes quenched endogenous peroxidase activity. Non-
specific binding sites were blocked using 2.5% serum of the species producing the 
secondary antibody diluted in PBS for 15 minutes. Staining was conducted using primary 
antibodies specific to E-Cadherin (1:200, Santa Cruz). Species-specific highly sensitive 
polymerized reporter enzymatic staining system (ImmPRESS Kits, Vector Labs) was 
used to conjugate horseradish perioxidase micropolymers to affinity-purified secondary 
antibodies with detection achieved by ImmPACT DAB perioxidase substrate (Vector 
Labs). Nuclei were counterstained with Harris Hematoxylin, dehydrated through graded 
alcohols, cleared in Xylenes, permanently mounted and imaged using a Zeiss Axiovert 
inverted fluorescent microscope. 
Western blotting 
Western blotting was performed as described previously in chapter 3. Where 
indicated, membranes were probed with primary antibodies: anti-ITGA11 (MAB4235, 
1:500, RD Systems), anti-GFP (JL-8, 1:1000, Clonetech,) anti-FAK (13009, 1:500, Cell 
Signaling Technologies), anti-Phospho-FAK (Tyr397) (8556, 1:500, Cell Signaling 
Technologies), anti-Phospho-FAK (Tyr576/577) (3281, 1:500, Cell Signaling 
Technologies), anti-Phospho-FAK (Tyr925) (3284, 1:500, Cell Signaling Technologies), 
anti-ECAD (sc-7870, 1:1000, Santa Cruz Biotechnologies), anti-ITGA11 (MAB4235, 
1:500, RD Systems), anti-actin (A2066, 1:10,000, Sigma). 
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GeneBank Symbol Description GO Term 
NM_002026 FN1 Fibronectin 1 
Cell adhesion;Extracellular;Oxidoreductase activity;Collagen 
binding;Extracellular matrix structural constituent;Heparin 
binding;Acute-phase response;Cell migration;Metabolism;Response 
to wounding; 
NM_002211 ITGB1 
Integrin, beta 1 (fibronectin 
receptor, beta polypeptide, 
antigen CD29 includes 
MDF2, MSK12) 
Integral to membrane;Protein binding;Development;Receptor 
activity;Homophilic cell adhesion;Cell-matrix adhesion;Integrin-
mediated signaling pathway;Integrin complex;Protein 
heterodimerization activity;Cellular defense response; 
NM_002205 ITGA5 Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
Integral to membrane;Protein binding;Receptor activity;Cell-matrix 
adhesion;Integrin-mediated signaling pathway;Integrin complex; 
NM_002290 LAMA4 Laminin, alpha 4 
Receptor binding;Protein binding;Extracellular matrix structural 
constituent;Regulation of cell adhesion;Regulation of cell 
migration;Regulation of embryonic development;Laminin-1; 
NM_003118 SPARC Secreted protein, acidic, cysteine-rich (osteonectin) 
Calcium ion binding;Collagen binding;Ossification;Basement 
membrane; 
NM_000358 TGFBI Transforming growth factor, beta-induced, 68kDa 
Cell adhesion;Cell proliferation;Protein binding;Negative regulation 
of cell adhesion;Extracellular matrix;Extracellular space;Integrin 
binding;Visual perception;Extracellular matrix (sensu Metazoa); 
NM_001846 COL4A2 Collagen, type IV, alpha 2 
Cytoplasm;Extracellular matrix structural constituent;Phosphate 
transport;Collagen;Extracellular matrix organization and 
biogenesis;Collagen type IV; 
NM_001850 COL8A1 Collagen, type VIII, alpha 1 
Cell adhesion;Protein binding;Cytoplasm;Extracellular matrix 
structural constituent;Phosphate transport;Extracellular matrix 
(sensu Metazoa);Collagen type VIII; 
NM_004385 VCAN Versican Calcium ion binding;Development;Hyaluronic acid binding;Cell recognition;Sugar binding;Extracellular matrix (sensu Metazoa); 
NM_001004439 ITGA11 Integrin, alpha 11 
Integral to membrane;Receptor activity;Collagen binding;Cell-matrix 
adhesion;Muscle development;Integrin-mediated signaling 
pathway;Integrin complex;Magnesium ion binding; 
NM_002204 ITGA3 
Integrin, alpha 3 (antigen 
CD49C, alpha 3 subunit of 
VLA-3 receptor) 
Integral to membrane;Protein binding;Receptor activity;Cell-matrix 
adhesion;Integrin-mediated signaling pathway;Integrin complex; 
NM_002421 MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 
Hydrolase activity;Calcium ion binding;Zinc ion binding;Interstitial 
collagenase activity;Collagen catabolism;Extracellular 
matrix;Extracellular space;Extracellular matrix (sensu Metazoa); 
NM_004530 MMP2 
Matrix metallopeptidase 2 
(gelatinase A, 72kDa 
gelatinase, 72kDa type IV 
collagenase) 
Hydrolase activity;Calcium ion binding;Zinc ion binding;Collagen 
catabolism;Extracellular matrix;Extracellular space;Gelatinase A 
activity;Extracellular matrix (sensu Metazoa); 
NM_002422 MMP3 
Matrix metallopeptidase 3 
(stromelysin 1, 
progelatinase) 
Hydrolase activity;Calcium ion binding;Zinc ion binding;Collagen 
catabolism;Extracellular space;Stromelysin 1 activity;Extracellular 
matrix (sensu Metazoa); 
NM_003919 SGCE Sarcoglycan, epsilon 
Calcium ion binding;Protein binding;Cell-matrix adhesion;Integral to 
plasma membrane;Cytoskeleton;Muscle development;Sarcoglycan 
complex; 
Appendix 1:  Genes Identified from Array
Appendix 2: Primers for all PCR 
Gene Sequence (5’—3’) 
CavIL GGATGTGCCTAGACCCGGCG 
CavIR GAACGGTGTAGAGATGTCCCTCCGA 
CavIIL GCAGAGCCGGTGACTACGCA 
CavIIR AGCATCGTCCTACGCTCGTACACA 
CavIIIL CGGCCACACAGCTCGGATCTC 
CaIIIR AGCTCACCTTCCACACGCCG 
ILKL AGCCCGAGTCCCGAGGATAAAGC 
ILKR CTCGGCAGGCCCAGTGCAAG 
CTNNB1L CCAATGGCTTGGAATGAGACTGCTG 
CTNNB1R CACCTGGAGGCAGCCCATCC 
FYNL CGTGGAAAAAGACCAGTCCTGCCT 
FYNR CCCGGCTGCGTGGAAGTTGT 
ILKL GAGTCCCGAGGATAAAGCTTGGGGT 
ILKR CTCGGCAGGCCCAGTGCAAG 
FN1L CTGGCCGAAAATACATTGTAAA 
FN1R CCACAGTCGGGTCAGGAG 
ITGB1L CGATGCCATCATGCAAGT 
ITGB1R AACAATGCCACCAAGTTTCC 
ITGB5L GGGCCTTTCTGTGAGTGC 
ITGB5R TGTAACCTGCATGGCACTTG 
LAMA4L AAGCGACCTGCAAGCAAC 
LAMA4R GCCATCAAACATCATGGAGAC 
SPARCL TTCCCTGTACACTGGCAGTTC 
SPARCR AATGCTCCATGGGGATGA 
TGFB1L CATTGGTGATGAAATCCTGGT 
TGFB1R TGACACTCACCACATTGTTTTTC 
COL4A2L GAGAAGGCGCACAACCAG 
COL4A2R CCGGCTGGCATAGTAGCA 
COL8A1L CATCTCAAGAACAAAAGACAACTGA 
COL8A1R TTGCTGGTGCCTTCCTGT 
ITGA11L GGTCTGTAAAAGATGTGGTGGAA 
ITGA11R CTTCTGGAAAGCCTCTGAGC 
ITGA3L CCCTCACTCCTTCTTCATGG 
ITGA3R GAGCTCCCACAGCAATATCC 
MMP1L GCATATCGATGCTGCTCTTTC 
MMP1R GATAACCTGGATCCATAGATCGTT 
MMP2L CGATGATGACCGCAAGTG 
MMP2R GGTCTTGGGAGTGCTCCAG 
MMP3L CTCCAACCGTGAGGAAAATC 
MMP3R CATGGAATTTCTCTTCTCATCAAA 
 
 
SGCEL CCACTGGCACATTCTTGCT 
SGCER TTCCAAAACATGAACAAAGAGG 
SPARCL GGAGGTGGTGGCGGAAAATCCC 
SPARCR GGGTCCTGGCACACGCACAT 
CAMK2N1L GCCGGAGCAAGCGGGTTGTTA 
CAMK2N1R CACCAGGAGGTGCCTTGTCGG 
MMP3L ACCTGACTCGGTTCCGCCTG 
MMP3R GTCAGGGGGAGGTCCATAGAGGG 
SPP1L GGCATCACCTGTGCCATACCAGT 
SPP1R TGGAAGGGTCTGTGGGGCTAGG 
FN1L CTGGCCTGGAACCGGGAACC 
FN1R ACCAGTTGGGGAAGCTCGTCTGT 
DSPL ATCAAAGCCGACCTGCGCGA 
DSPR AGCAGCTCCTCCTCCTCGCA 
TCF4L AGCCATGGGTGGTCTGGGCT 
TCF4R ACGATGGGTCCCCACCATGA 
Primer	   Sequence	  (5’—3’)	   Amplicon(bp)	  
ITGA11CpG1L	   GGAGCGGTTCTCTGGAGTTT	   196	  
ITGA11CpG1R	   TGCGGCTCATTCAGAGGAAG	   	  
ITGA11CpG2L	   CTCCGGGGAAGCATCTCAAA	   109	  
ITGA11CpG2R	   CTTTGCTCTGTCTTTGGCCG	   	  
ITGA11CpG3L	   CCGGGACTCTTTGGTGTGTT	   197	  
ITGA11CpG3R	   TCTTGGCGCTGATTCCCTTC	   	  
ITGA11CpG4L	   CTCCGGGGAAGCATCTCAAA	   109	  
ITGA11CpG4R	   CTTTGCTCTGTCTTTGGCCG	   	  
ITGA11CpG5L	   TAATGCACTCCAGGTGTCGG	   180	  
ITGA11CpG5R	   TTCCGCAGAACAGCATCACT	   	  
